Supplementary Figures



Figure S1: **WDLS/DDLS tumors and the two cell lines used in this study have complex DNA copy number alterations.** Unified break points of DNA copy numbers of a set of WDLS and DDLS tumors and tumor-derived cell lines profiled with array-comparative genomic hybridization (aCGH, Agilent 244K array) and analyzed with the RAE algorithm (*53*). RAE scores were clustered using the Manhattan length as distances measure. Two IGV-viewer snap shots centered around DDLS8817 and LPS141 are shown. In this work, we selected the two cell lines, DDLS8817 and LPS141, which are derived from patients with dedifferentiated liposarcoma. Similar to WDLS/DDLS tumors, the selected cell lines exhibit complex DNA alterations across the genome. Furthermore, the cell lines also have the distinct hall-mark of WDLS/DDLS: focal amplification of 12q13-15 (green arrow) haboring the oncogenes *CDK4*, *HMGA*, and *MDM2*. Note that the cell lines do not form their own outliers when clustered with tumors, indicating that the selected cell lines have alterations in common with the WDLS/DDLS tumors. CNA data from tumor samples were obtained from Crago et al., 2012 (*19*).



Figure S2: **EC50 determination using a cell metabolic activity assay shows good agreement between biological replicates.** DDLS8817 cells were grown in 96 well plates and perturbed with seven different concentrations of each drug and the effect on cell metabolic activity (a correlate of cell viability) was measured by the Resazurin assay after three days of drug treatment. Inhibitors of specific gene targets as indicated (for example AKTi for AKT inhibitor). For list drugs used please see **table S1**. After normalization to untreated controls (DMSO), EC50 values were obtained from sigmoid fitted dose-response curves. At least four independent biological replicates of the EC50 determination are depicted.



Figure S3: **Effects of PD0332991 and NVP-AEW541 in DDLS8817 and LPS141 cells.** Drug effect on cell proliferation was tested using the CCK-8 assay after 6 days of drug treatment with 1 μM of the small molecule NVP-AEW541 (IGF1Ri), or with 1 μM PD0332991 (CDK4i), or with both drugs in combination. Cell metabolic activity (viability) was normalized to non-treated controls (DMSO). Error bars represents standard deviation of five biological replicates.



Figure S4: **CDK4 inhibition causes G1 cell cycle arrest in LPS141 cells.** Cellular DNA content measured by flow cytometry of LPS141 cells treated for 24 hours with 1 μM of PD0332991 (CDK4i), 10 μg/mL R1507 (anti-IGF1R antibody), or 1 μM of NVP-AEW541 (IGF1Ri), or siRNA targeted to CDK4. Note that PD0332991 and CDK4-siRNA treatment both result in a pronounced G1 arrest making the effects of the combination treatments difficult to assess. However, compared to single treatment with PD0332991, the combined inhibition with PD0332991 and R1507 results in small but noticeably enhanced G1 arrest. The data depicted are representative data of at least two independently performed experiments.



Figure S5: **Phosphorylation of AKT in DDLS8817 cells is consistently suppressed for at least 24h after PI3K inhibition.** To determine an appropriate time-frame for proteomic profiling with RPPA, we tested the effect of PI3K inhibition (PI3K inhibitor IV) at the indicated time points using Western blotting for phosphorylated AKT (at Ser^{473}). Note that phosphorylation of AKT is consistently suppressed in the time period tested, although higher concentrations are needed to obtain the same effect at later time points. The data depicted are representative data.



Figure S6: **Examples of determining the appropriate drug concentration for RPPA-based proteomic profiling in DDLS8817 cells.** To select a suitable drug concentration for our systematic perturbation screen using the RPPA assay, we tested each drug by measuring the effect on the presumed drug target or down-stream target using Western blotting. Drugs were administered for 24h before cell lysis was performed. The Western blot data depicted are representative data. In cases where protein-based IC40 levels could be determined (middle panel), the corresponding drug concentration was used in the RPPA-screen. For comparison, the effect on cell viability based on cell metabolic activity is shown (right panel, 72h treatment, Resazurin assay). Error bars represent standard deviation of at least four biological replicates. Note that the doses needed for observing changes on a molecular level is about an order of magnitude lower than those needed for observing effects on a phenotypic level.



Figure S7: **Western blot testing of antibodies used in the RPPA assay shows no apparent cross-reactivity.** Lack of antibody specificity is a potential concern with the RPPA technique as antibody cross-reactivity with non-target antigens are not readily apparent compared to other methods that use protein size separation (e.g. Western blotting). To address this concern, we collected protein lysate from both DDLS8817 and LPS141 cells and performed Western blot analysis using the set of antibodies that were used in the RPPA experiment but that had not been validated already (for the additional antibodies, please see **Fig. 7A** and **B** in the main text). Each cell line was assayed using two biological replicates. Note that for all antibody tested, the only band that appears on the blot is the band that corresponds to the molecular weight of the antibody target (protein ladder is indicated). For LPS141, which was not used in the RPPA assay and therefore not in the network modeling, the signal for PKCa and phosphorylated MEK (at Ser^{217}) were below detection. These results indicate that the antibodies used in the RPPA assay have no apparent cross-reactivity in the cell lines analyzed in this study.



Figure S8: **mRNA expression of nodes in the network fall in the top half of all genes in both cell lines used.** Ranked mRNA transcript expression for all genes in DDLS8817 (**A**) and LPS141 (**B**) cells growing in basal conditions. Transcripts were profiled using the Illumina HT 12 V3 platform and genes with multiple probes were averaged. Highlighted are genes in the network that were measured (yellow) and genes that were only inhibited but not measured (red). Error bars represent standard deviation of three biological replicates. For clarity, error bars are only displayed for nodes used in the network.



Figure S9: **DNA copy number analysis of network genes shows copy gains in multiple genes and amplification of CDK4.** An IGV-viewer snap shot of unified break points of DNA copy numbers of DDLS8817 and LPS141 cells profiled with Agilent 244K array comparative genomic hybridization (aCGH) and analyzed with the RAE algorithm (*53*). Only the genes used in the network models are displayed. Note that while multiple of the genes studied have copy number gains, only CDK4 for DDLS8817 and LPS141 and EGFR for LPS141 have high-level amplifications. No homozygous deletions were detected.



Figure S10: **Schematic illustration of the computational analysis on a fictional 4-node system. A**, Belief propagation produces probability distributions for each of the N^2 possible model parameters. Individual models are created by drawing from these probability distributions accordingly. **B**, A single executable model connects interacting nodes. The model equation describes the dynamics of the model in response to an external perturbation (black line, u_i). **C**, An example simulation in response to inhibition of the third node relaxes to a steady state. We take this steady state to be the model-predicted response of the cell to this perturbation condition.



Figure S11: **Network models are not over-fitted to prior knowledge interactions.** Bar chart depicting the percent of prior knowledge interactions (total of 34) that are retained in the inferred networks under different conditions. Incorporating prior knowledge interactions for network modeling has several advantages (see Discussion), but a potential concern is that the models are too constrained to the prior knowledge interactions. Not all prior knowledge interactions (blue bars) are retained in the network models (26 out of 34), reflecting that prior knowledge interactions are softly encoded in our modeling approach and are rejected if they do not fit with the perturbation-response profiles. Scrambling the input data reduces the number of retained prior knowledge interactions significantly (from 26 to 17 $p<6.2E-13$, student's t-test). This shows that the models are not over-fitted to the prior knowledge interactions as many of these are supported by perturbation-response data. The random chance of capturing the prior knowledge interactions out of the total set of interactions is indicated. Gray bars represent the number of predicted interactions of all possible interactions (378 with 14 measured nodes and 14 activity nodes). Error bars represent standard deviation of 14 leave-k-out cross-validation sets.



Figure S12: **BP improves performance of prior knowledge interactions alone.** We evaluate model performance with the mean squared error (MSE), which is here calculated as the sum of squared error between measured and model estimated data points normalized by the number of data points. It is difficult, however, to know how meaningful any MSE value is. We therefore calculate the MSE on a set of random models (red distribution). The random models are constrained to have the same number of positive and negative interactions as in the prior-knowledge network, but are otherwise randomly parametrized. The prior-knowledge topology, optimized with 100 uniquely initialized parameter assignments (green distribution), perform better than random models as is evident by the nearly complete separation between the two distributions. This separation suggest that while the prior knowledge models by themselves are not the best performing models, they do collectively describe models that are more consistent with the data than one would expect by random. The prior knowledge interactions are used to guide Bayesian Network inference (*58, 59*) (with BioLearn 1.0 software), which yield even better performing models (yellow distribution). BioLearn was run with the prior knowledge network incorporated as the starting search topology, and 100 topologies were then produced, converted into ODE models, and optimized with the same gradient descent method used for this work (*57*). The prior-knowledge guided BP-derived models (blue distribution) clearly demonstrate improved performance compared to all three other methods, suggesting that indeed BP adds significant descriptive value to the set of prior knowledge interactions selected in this work.



Figure S13: **BP inference is minimally sensitive to drug-specificity.** Values on the x-axis are BP distribution averages when we assume no off-target effects; each drug acts on a single model target. Values on the y-axis are BP distribution averages when randomly added off-target contributions are assumed (random values between 0 and –0.5 corresponding to half max perturbation strength); each drug acts predictably on its main target but also influences other nodes. This analysis suggests that BP is not prohibitively sensitive to exact knowledge of all off-target effects.



Figure S14: **Liposarcoma-specific network models are predictive of cell response to drugs.** Using the 100 lowest error models from each of the leave-k-out network models, the activity node (drug target) in question was inhibited in combination with all other nodes and the effect on the cell viability node was recorded. We found a reasonable correlation between the experimental and predicted inhibition of cell viability (Pearson Correlation Coefficient $= 0.815$). Experimental cell viability was estimated by cell metabolic activity measurements using the Resazurin assay. As the predicted effect on cell viability relies on the information being propagated through the network models, this reasonable correlation indicates that the network models capture biologically relevant signaling connectivities in DDLS8817.



Figure S15: **Many of the drug combinations with the strongest predicted synergy scores are categorized in accordance with experiments.** The predicted synergy score, S, of each paired node inhibition was compared to the experimentally obtained synergy score [$\log_2$ of combination index (CI) score], and a positive but non-significant correlation was found (Pearson Correlation Coefficient $= 0.23$, $p = 0.07$). Inset shows average of synergy scores with bin sizes $\Delta S = 0.2$. The predicted synergy scores were obtained using the leave-k-out cross validation approach to avoid training and predicting on the same data. Note that, although many of the drug combinations with the strongest predicted synergistic and antagonistic effects were categorized in accordance with the experiments, several predictions were miscategorized (see Discussion).



Figure S16: **Combined inhibition of the CDK4 and IGF1R nodes is predicted to be synergistic by the network models. A,** Using the top 100 network models based on measurements where all dual perturbations with IGF1R inhibitor were left out, the two activity nodes (drug targets) aCDK4 and aIGF1R were inhibited with eight different strengths (u). The effect on the cell viability node was recorded where positive and negative values (z-scores) represent activating and inhibiting effects on cell viability, respectively. Note that, inhibition of aCDK4 resulted in an increase of cell viability; an effect that is consistent with our training data from low drug doses, but inconsistent with the drug synergy experiment where much higher drug doses were used. **B,** Non-additive effects were determined as the difference between the effect of the paired simulated perturbation (Z_{sim}) and a Loewe additivity surface (Z_{loewe}) derived from the added effects of the single node perturbations, $S = \sum(Z_{sim}$ - $Z_{loewe})$. The aIGF1R and aCDK4 synergy score was calculated to -0.23. **C,** To determine if the predicted synergy score for the aIGF1R and aCDK4 combination could be expected by random chance, 75 of the top 100 models were randomly resampled 1000 times. Using these bootstrap samples, the synergy score was recalculated and the distribution of synergy scores is displayed (gray). Similarly, a background distribution of synergy scores was obtained by perturbing the same nodes in a similar procedure but using random but similarly parameterized models (blue). The two distributions were found to be significantly different ($p < 5.5\text{E}{-98}$, Wilcoxon rank test).



Figure S17: **Combination treatment enhances repression of mTOR signaling compared to single drug treatment.** Quantified Western blot readouts of DDLS8817 (left) and LPS141 (right) cells treated for 24 hours with the indicated conditions. The bands for the indicated antibodies were quantified using optical density analysis and the intensities were normalized to vehicle-treated control cells (DMSO). Error bars represent standard deviation of three biological replicates. Significance values using unpaired, two-tailed t-tests between the combination treatment and the strongest of the single drug treatments are indicated. Note that, while a significantly enhanced effect of the combined treatment was observed for mTOR signaling (three of four for p70S6K-pThr^{389} and S6-pSer$^{235-236}$, **BC**), a similar but non-significant trends was observed on AKT signaling (AKT-pSer^{473}, **A**).



Figure S18: **Inhibition of EGFR and CDK4 has synergistic effects on cell metabolic activity and effects are enhanced in a triple perturbation adding an IGF1R inhibitor.** Dose-response measurements of cell viability based on cell metabolic activity of DDLS8817 (left panel) and LPS141 cells (right panel) after drug administration for 6 days with (**A**) Erlotinib (EGFRi) and PD0332991 (CDK4i), (**B**) R1507 (IGF1Ri) and PD0332991, and (**C**) all three drugs using the CCK-8 assay. In (**C**), single inhibition with Erlotinib and dual treatment with PD0332991 and R1507 and compared to the effect of all three drugs combined. The combination index (CI) scores were determined at EC50 levels indicated by dashed lines. To compare between conditions, drug concentrations were normalized to the highest concentration used. The highest drug concentrations used were 25.6μM for Erlotinib, 1.28μM for PD0332991, and 16μg/ml for R1507. Error bars represent standard deviation of six biological replicates.



Figure S19: **Combining CDK4 inhibition with MEK or ERK inhibition does not result in synergistic effects on cell viability based on cell metabolic activity.** Cell viability based on cell metabolic activity of DDLS8817 (left panel) and LPS141 (right panel) was measured after 3 days of drug inhibition with PD0332991 (1 μM, CDK4i), AZD6244 (1 μM, MEKi), or FR180204 (2.5 μM, ERKi). Cell viability was normalized to non-treated controls (DMSO). Note that the effect of combining CDK4i with ERKi or MEKi is similar to CDK4i treatment alone, indicating that MAPK-pathway inhibitors do not synergize with CDK4i. Error bars represent standard deviation of five biological replicates.



Figure S20: **Many of the top 100 models predict synergistic effects of combined CDK4 and IGF1R inhibition.** Distribution of predicted synergy scores, S, after inhibition of the CDK4 and IGF1R nodes using the top 100 models. The top 100 models were trained based on data where all drug pairs involving IGF1R inhibitor were left out. Applying the previously used cut off of $S < -0.2$ for classifying synergy (**Fig. 5**, main text), 20 of the top models predicted strong synergy between CDK4 and IGF1R. Note that only 66 of the top 100 models could be used in this analysis, because 34 models resulted in activation of the cell viability node and synergy could not be computed.

Supplementary Tables

Table S1: **Drugs used in the synergy screen (cell viability) and the proteomic screen (RPPA).** Drugs and their primary targets are listed. Genes that have also been shown to be inhibited at high concentrations are listed (Secondary Targets). The drug concentration used in the RPPA assay is indicated and was selected based on either protein IC40 measured by Western blotting (rule P for protein, see **fig. S6**) or information obtained from literature (rule L for literature). Finally, the concentration range for the drug synergy screen (based on cell viability) is listed. *Indicates the concentration range used in dose-response cell viability experiments with 2 fold serial dilutions unless otherwise stated.

Drug	**Primary Targets**	**Secondary Targets** (at high conc)	**Company**	**Product#**	**Conc** (RPPA)	**Rule**	**Conc*** (cell viability)
AG538	IGF1R	EGFR	EMD Millipore	658403	0.5 μM	L	20 — 0.3 μM
AKT 1/2 Inh	AKT1/2		EMD Millipore	124018	0.1 μM	P	20 — 0.3 μM
FR180204	ERK1/2	p38	EMD Millipore	328007	1.5 μM	L	5 — 0.08 μM
Gefitinib	EGFR		Tocris	3000	0.8 μM	P	20 — 0.3 μM
HNHA	HDAC		Cayman	13295	0.08 μM	P	20 — 0.3 μM
PDGFR TKI III	PDGFR	KIT	EMD Millipore	521232	0.23 μM	L	10 — 0.2 μM
PI3Ka Inh IV	PI3K(PIK3CA/2A/2B)		EMD Millipore	528111	0.03 μM	P	4 — 0.06 μM
Rapamycin	mTOR		Selleckchem	1039	1 pM	L	0.1 μM — 0.1 pM
Rottlerin	PKC/CaMKIII	PKC isoforms	Tocris	1610	0.125 μM	L	5 — 0.08 μM
Ryuvidine	CDK4/6	CDK2	Tocris	2609	0.1 μM	L	2 — 0.03 μM
SL327	MEK1/2	JNK	EMD Millipore	444939	4 μM	P	5 — 0.08 μM
SRC Inh I	SRC	LCK	EMD Millipore	567805	2.4 μM	L	5 — 0.08 μM
Stattic	STAT3		EMD Millipore	573099	0.075 μM	L	0.4 — 0.006 μM
SU11247	MET		EMD Millipore	448101	0.5 μM	L	20 — 0.3 μM

Table S2: **Dose-response measurements of single and paired drug perturbations using the Resazurin assay.** In each experiment (named by date and drug combination) seven drug concentrations were used (C1-C7, two fold dilution series). The drugs were administered individually at the doses indicated or in combinations with the doses corresponding to those used for the single drugs (for example 5 μM AKT inhibitor and 2 μM PI3K inhibitor for AK.PK.C5). The estimated effect on cell viability (the assay measures metabolic activity) was determined relative to control (DMSO treated). At least four biological replicates were performed for each condition and the standard deviations are indicated. The abbreviations of the drugs and their main targets are as follows; AG: IGF1R, AK: AKT, ER: ERK, GF: EGFR, HN: HDAC, PD: PDGFR, PI: PI3K, RT: PKC, RY: CDK4, SL: MEK, SR: SRC, ST: STAT3, SU: MET. Please see **table S1** for drug names.

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091112.AK.PI	AK.C1	0.3125	1.216	0.12	20100202.AK.ER	AK.C1	0.3125	0.983	0.036
20091112.AK.PI	AK.C2	0.625	0.995	0.1	20100202.AK.ER	AK.C2	0.625	0.895	0.056
20091112.AK.PI	AK.C3	1.25	0.98	0.097	20100202.AK.ER	AK.C3	1.25	0.887	0.081
20091112.AK.PI	AK.C4	2.5	0.926	0.037	20100202.AK.ER	AK.C4	2.5	0.785	0.072
20091112.AK.PI	AK.C5	5	0.722	0.043	20100202.AK.ER	AK.C5	5	0.587	0.034
20091112.AK.PI	AK.C6	10	0.412	0.018	20100202.AK.ER	AK.C6	10	0.399	0.04
20091112.AK.PI	AK.C7	20	0.264	0.022	20100202.AK.ER	AK.C7	20	0.277	0.034
20091112.AK.PI	AK.PI.C1	AK.PI.C1	0.927	0.051	20100202.AK.ER	AK.ER.C1	AK.ER.C1	0.965	0.042
20091112.AK.PI	AK.PI.C2	AK.PI.C2	0.781	0.039	20100202.AK.ER	AK.ER.C2	AK.ER.C2	0.929	0.081
20091112.AK.PI	AK.PI.C3	AK.PI.C3	0.588	0.025	20100202.AK.ER	AK.ER.C3	AK.ER.C3	0.906	0.058
20091112.AK.PI	AK.PI.C4	AK.PI.C4	0.472	0.028	20100202.AK.ER	AK.ER.C4	AK.ER.C4	0.88	0.062
20091112.AK.PI	AK.PI.C5	AK.PI.C5	0.32	0.027	20100202.AK.ER	AK.ER.C5	AK.ER.C5	0.697	0.053
20091112.AK.PI	AK.PI.C6	AK.PI.C6	0.238	0.012	20100202.AK.ER	AK.ER.C6	AK.ER.C6	0.422	0.066
20091112.AK.PI	AK.PI.C7	AK.PI.C7	0.141	0.009	20100202.AK.ER	AK.ER.C7	AK.ER.C7	0.27	0.048
20091112.AK.PI	PI.C1	0.125	1.023	0.061	20100202.AK.ER	ER.C1	0.078125	1.01	0.025
20091112.AK.PI	PI.C2	0.25	0.788	0.042	20100202.AK.ER	ER.C2	0.15625	1.053	0.037
20091112.AK.PI	PI.C3	0.5	0.636	0.039	20100202.AK.ER	ER.C3	0.3125	1.026	0.038
20091112.AK.PI	PI.C4	1	0.433	0.036	20100202.AK.ER	ER.C4	0.625	1.019	0.048
20091112.AK.PI	PI.C5	2	0.323	0.017	20100202.AK.ER	ER.C5	1.25	1.001	0.062
20091112.AK.PI	PI.C6	4	0.253	0.015	20100202.AK.ER	ER.C6	2.5	0.969	0.069
20091112.AK.PI	PI.C7	8	0.225	0.02	20100202.AK.ER	ER.C7	5	0.949	0.114
20091112.AK.SU	AK.C1	0.3125	1.216	0.12	20100202.AK.GF	AK.C1	0.3125	0.983	0.036
20091112.AK.SU	AK.C2	0.625	0.995	0.1	20100202.AK.GF	AK.C2	0.625	0.895	0.056
20091112.AK.SU	AK.C3	1.25	0.98	0.097	20100202.AK.GF	AK.C3	1.25	0.887	0.081
20091112.AK.SU	AK.C4	2.5	0.926	0.037	20100202.AK.GF	AK.C4	2.5	0.785	0.072
20091112.AK.SU	AK.C5	5	0.722	0.043	20100202.AK.GF	AK.C5	5	0.587	0.034
20091112.AK.SU	AK.C6	10	0.412	0.018	20100202.AK.GF	AK.C6	10	0.399	0.04
20091112.AK.SU	AK.C7	20	0.264	0.022	20100202.AK.GF	AK.C7	20	0.277	0.034
20091112.AK.SU	AK.SU.C1	AK.SU.C1	0.896	0.036	20100202.AK.GF	AK.GF.C1	AK.GF.C1	0.855	0.039
20091112.AK.SU	AK.SU.C2	AK.SU.C2	0.996	0.048	20100202.AK.GF	AK.GF.C2	AK.GF.C2	0.809	0.062
20091112.AK.SU	AK.SU.C3	AK.SU.C3	0.821	0.062	20100202.AK.GF	AK.GF.C3	AK.GF.C3	0.725	0.057
20091112.AK.SU	AK.SU.C4	AK.SU.C4	0.674	0.035	20100202.AK.GF	AK.GF.C4	AK.GF.C4	0.658	0.023
20091112.AK.SU	AK.SU.C5	AK.SU.C5	0.391	0.03	20100202.AK.GF	AK.GF.C5	AK.GF.C5	0.357	0.013
20091112.AK.SU	AK.SU.C6	AK.SU.C6	0.21	0.016	20100202.AK.GF	AK.GF.C6	AK.GF.C6	0.159	0.008
20091112.AK.SU	AK.SU.C7	AK.SU.C7	0.015	0.001	20100202.AK.GF	AK.GF.C7	AK.GF.C7	0.01	0.001
20091112.AK.SU	SU.C1	0.3125	1.08	0.138	20100202.AK.GF	GF.C1	0.3125	1.001	0.04
20091112.AK.SU	SU.C2	0.625	1.061	0.171	20100202.AK.GF	GF.C2	0.625	0.976	0.063
20091112.AK.SU	SU.C3	1.25	0.861	0.097	20100202.AK.GF	GF.C3	1.25	1.042	0.113
20091112.AK.SU	SU.C4	2.5	0.806	0.038	20100202.AK.GF	GF.C4	2.5	0.93	0.111
20091112.AK.SU	SU.C5	5	0.645	0.044	20100202.AK.GF	GF.C5	5	0.903	0.116
20091112.AK.SU	SU.C6	10	0.444	0.03	20100202.AK.GF	GF.C6	10	0.702	0.084
20091112.AK.SU	SU.C7	20	0.282	0.02	20100202.AK.GF	GF.C7	20	0.366	0.058
20091112.PI.SU	PI.C1	0.125	1.023	0.061	20100202.ER.GF	ER.C1	0.078125	1.01	0.025
20091112.PI.SU	PI.C2	0.25	0.788	0.042	20100202.ER.GF	ER.C2	0.15625	1.053	0.037
20091112.PI.SU	PI.C3	0.5	0.636	0.039	20100202.ER.GF	ER.C3	0.3125	1.026	0.038
20091112.PI.SU	PI.C4	1	0.433	0.036	20100202.ER.GF	ER.C4	0.625	1.019	0.048
20091112.PI.SU	PI.C5	2	0.323	0.017	20100202.ER.GF	ER.C5	1.25	1.001	0.062
20091112.PI.SU	PI.C6	4	0.253	0.015	20100202.ER.GF	ER.C6	2.5	0.969	0.069
20091112.PI.SU	PI.C7	8	0.225	0.02	20100202.ER.GF	ER.C7	5	0.949	0.114
20091112.PI.SU	PI.SU.C1	PI.SU.C1	0.93	0.038	20100202.ER.GF	ER.GF.C1	ER.GF.C1	0.944	0.039
20091112.PI.SU	PI.SU.C2	PI.SU.C2	0.799	0.067	20100202.ER.GF	ER.GF.C2	ER.GF.C2	0.935	0.036
20091112.PI.SU	PI.SU.C3	PI.SU.C3	0.588	0.05	20100202.ER.GF	ER.GF.C3	ER.GF.C3	0.924	0.043
20091112.PI.SU	PI.SU.C4	PI.SU.C4	0.536	0.067	20100202.ER.GF	ER.GF.C4	ER.GF.C4	0.901	0.033
20091112.PI.SU	PI.SU.C5	PI.SU.C5	0.268	0.031	20100202.ER.GF	ER.GF.C5	ER.GF.C5	0.805	0.037
20091112.PI.SU	PI.SU.C6	PI.SU.C6	0.171	0.029	20100202.ER.GF	ER.GF.C6	ER.GF.C6	0.654	0.056
20091112.PI.SU	PI.SU.C7	PI.SU.C7	0.099	0.007	20100202.ER.GF	ER.GF.C7	ER.GF.C7	0.28	0.01
20091112.PI.SU	SU.C1	0.3125	1.08	0.138	20100202.ER.GF	GF.C1	0.3125	1.001	0.04
20091112.PI.SU	SU.C2	0.625	1.061	0.171	20100202.ER.GF	GF.C2	0.625	0.976	0.063
20091112.PI.SU	SU.C3	1.25	0.861	0.097	20100202.ER.GF	GF.C3	1.25	1.042	0.113
20091112.PI.SU	SU.C4	2.5	0.806	0.038	20100202.ER.GF	GF.C4	2.5	0.93	0.111
20091112.PI.SU	SU.C5	5	0.645	0.044	20100202.ER.GF	GF.C5	5	0.903	0.116

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091112.PI.SU	SU.C6	10	0.444	0.03	20100202.ER.GF	GF.C6	10	0.702	0.084
20091112.PI.SU	SU.C7	20	0.282	0.02	20100202.ER.GF	GF.C7	20	0.366	0.058
20091116.GF.HN	GF.C1	0.625	1.171	0.129	20100205.HN.ST	HN.C1	0.3125	0.992	0.037
20091116.GF.HN	GF.C2	1.25	1.131	0.137	20100205.HN.ST	HN.C2	0.625	0.969	0.053
20091116.GF.HN	GF.C3	2.5	0.801	0.038	20100205.HN.ST	HN.C3	1.25	0.909	0.037
20091116.GF.HN	GF.C4	5	0.803	0.073	20100205.HN.ST	HN.C4	2.5	0.765	0.038
20091116.GF.HN	GF.C5	10	0.661	0.076	20100205.HN.ST	HN.C5	5	0.656	0.024
20091116.GF.HN	GF.C6	20	0.21	0.019	20100205.HN.ST	HN.C6	10	0.349	0.025
20091116.GF.HN	GF.C7	40	-0.003	0.002	20100205.HN.ST	HN.C7	20	0.098	0.022
20091116.GF.HN	GF.HN.C1	GF.HN.C1	1.042	0.046	20100205.HN.ST	HN.ST.C1	HN.ST.C1	0.924	0.033
20091116.GF.HN	GF.HN.C2	GF.HN.C2	0.983	0.022	20100205.HN.ST	HN.ST.C2	HN.ST.C2	0.926	0.03
20091116.GF.HN	GF.HN.C3	GF.HN.C3	0.965	0.101	20100205.HN.ST	HN.ST.C3	HN.ST.C3	0.833	0.038
20091116.GF.HN	GF.HN.C4	GF.HN.C4	0.8	0.049	20100205.HN.ST	HN.ST.C4	HN.ST.C4	0.495	0.096
20091116.GF.HN	GF.HN.C5	GF.HN.C5	0.575	0.05	20100205.HN.ST	HN.ST.C5	HN.ST.C5	0.201	0.018
20091116.GF.HN	GF.HN.C6	GF.HN.C6	0.251	0.046	20100205.HN.ST	HN.ST.C6	HN.ST.C6	0.024	0.002
20091116.GF.HN	GF.HN.C7	GF.HN.C7	0.003	0.001	20100205.HN.ST	HN.ST.C7	HN.ST.C7	0.013	0.001
20091116.GF.HN	HN.C1	0.3125	0.995	0.06	20100205.HN.ST	ST.C1	0.078125	1.05	0.013
20091116.GF.HN	HN.C2	0.625	1.129	0.149	20100205.HN.ST	ST.C2	0.15625	1.048	0.024
20091116.GF.HN	HN.C3	1.25	1.018	0.066	20100205.HN.ST	ST.C3	0.3125	0.96	0.023
20091116.GF.HN	HN.C4	2.5	0.976	0.07	20100205.HN.ST	ST.C4	0.625	0.629	0.032
20091116.GF.HN	HN.C5	5	1.074	0.162	20100205.HN.ST	ST.C5	1.25	0.333	0.018
20091116.GF.HN	HN.C6	10	0.69	0.042	20100205.HN.ST	ST.C6	2.5	0.039	0.004
20091116.GF.HN	HN.C7	20	0.27	0.026	20100205.HN.ST	ST.C7	5	0.009	0.001
20091116.HN.RT	HN.C1	0.3125	0.995	0.06	20100205.HN.SU	HN.C1	0.3125	0.992	0.037
20091116.HN.RT	HN.C2	0.625	1.129	0.149	20100205.HN.SU	HN.C2	0.625	0.969	0.053
20091116.HN.RT	HN.C3	1.25	1.018	0.066	20100205.HN.SU	HN.C3	1.25	0.909	0.037
20091116.HN.RT	HN.C4	2.5	0.976	0.07	20100205.HN.SU	HN.C4	2.5	0.765	0.038
20091116.HN.RT	HN.C5	5	1.074	0.162	20100205.HN.SU	HN.C5	5	0.656	0.024
20091116.HN.RT	HN.C6	10	0.69	0.042	20100205.HN.SU	HN.C6	10	0.349	0.025
20091116.HN.RT	HN.C7	20	0.27	0.026	20100205.HN.SU	HN.C7	20	0.098	0.022
20091116.HN.RT	HN.RT.C1	HN.RT.C1	0.89	0.082	20100205.HN.SU	HN.SU.C1	HN.SU.C1	0.968	0.01
20091116.HN.RT	HN.RT.C2	HN.RT.C2	0.999	0.05	20100205.HN.SU	HN.SU.C2	HN.SU.C2	1	0.038
20091116.HN.RT	HN.RT.C3	HN.RT.C3	0.808	0.032	20100205.HN.SU	HN.SU.C3	HN.SU.C3	0.919	0.037
20091116.HN.RT	HN.RT.C4	HN.RT.C4	0.773	0.057	20100205.HN.SU	HN.SU.C4	HN.SU.C4	0.713	0.089
20091116.HN.RT	HN.RT.C5	HN.RT.C5	0.528	0.059	20100205.HN.SU	HN.SU.C5	HN.SU.C5	0.411	0.031
20091116.HN.RT	HN.RT.C6	HN.RT.C6	0.249	0.036	20100205.HN.SU	HN.SU.C6	HN.SU.C6	0.209	0.015
20091116.HN.RT	HN.RT.C7	HN.RT.C7	0.027	0.005	20100205.HN.SU	HN.SU.C7	HN.SU.C7	0.026	0.014
20091116.HN.RT	RT.C1	0.0625	1.01	0.076	20100205.HN.SU	SU.C1	0.3125	1.086	0.089
20091116.HN.RT	RT.C2	0.125	0.786	0.045	20100205.HN.SU	SU.C2	0.625	0.991	0.084
20091116.HN.RT	RT.C3	0.25	0.766	0.042	20100205.HN.SU	SU.C3	1.25	0.887	0.096
20091116.HN.RT	RT.C4	0.5	0.672	0.062	20100205.HN.SU	SU.C4	2.5	0.835	0.057
20091116.HN.RT	RT.C5	1	0.494	0.044	20100205.HN.SU	SU.C5	5	0.607	0.059
20091116.HN.RT	RT.C6	2	0.209	0.069	20100205.HN.SU	SU.C6	10	0.492	0.087
20091116.HN.RT	RT.C7	4	0.106	0.009	20100205.HN.SU	SU.C7	20	0.313	0.043
20091209.ER.SL	ER.C1	0.3125	1.022	0.046	20100205.ST.SU	ST.C1	0.078125	1.05	0.013
20091209.ER.SL	ER.C2	0.625	1.002	0.067	20100205.ST.SU	ST.C2	0.15625	1.048	0.024
20091209.ER.SL	ER.C3	1.25	1.004	0.04	20100205.ST.SU	ST.C3	0.3125	0.96	0.023
20091209.ER.SL	ER.C4	2.5	0.967	0.038	20100205.ST.SU	ST.C4	0.625	0.629	0.032
20091209.ER.SL	ER.C5	5	0.973	0.027	20100205.ST.SU	ST.C5	1.25	0.333	0.018
20091209.ER.SL	ER.C6	10	1.004	0.031	20100205.ST.SU	ST.C6	2.5	0.039	0.004
20091209.ER.SL	ER.C7	20	0.829	0.045	20100205.ST.SU	ST.C7	5	0.009	0.001
20091209.ER.SL	ER.SL.C1	ER.SL.C1	0.898	0.09	20100205.ST.SU	ST.SU.C1	ST.SU.C1	1.044	0.035
20091209.ER.SL	ER.SL.C2	ER.SL.C2	0.887	0.088	20100205.ST.SU	ST.SU.C2	ST.SU.C2	1.046	0.043
20091209.ER.SL	ER.SL.C3	ER.SL.C3	0.917	0.036	20100205.ST.SU	ST.SU.C3	ST.SU.C3	0.939	0.042
20091209.ER.SL	ER.SL.C4	ER.SL.C4	1.043	0.044	20100205.ST.SU	ST.SU.C4	ST.SU.C4	0.646	0.035
20091209.ER.SL	ER.SL.C5	ER.SL.C5	0.984	0.052	20100205.ST.SU	ST.SU.C5	ST.SU.C5	0.271	0.013
20091209.ER.SL	ER.SL.C6	ER.SL.C6	0.888	0.047	20100205.ST.SU	ST.SU.C6	ST.SU.C6	0.026	0.002
20091209.ER.SL	ER.SL.C7	ER.SL.C7	0.83	0.052	20100205.ST.SU	ST.SU.C7	ST.SU.C7	0.011	0.002
20091209.ER.SL	SL.C1	0.3125	1.311	0.091	20100205.ST.SU	SU.C1	0.3125	1.086	0.089
20091209.ER.SL	SL.C2	0.625	1.133	0.216	20100205.ST.SU	SU.C2	0.625	0.991	0.084
20091209.ER.SL	SL.C3	1.25	1.03	0.152	20100205.ST.SU	SU.C3	1.25	0.887	0.096
20091209.ER.SL	SL.C4	2.5	0.898	0.068	20100205.ST.SU	SU.C4	2.5	0.835	0.057
20091209.ER.SL	SL.C5	5	0.904	0.045	20100205.ST.SU	SU.C5	5	0.607	0.059
20091209.ER.SL	SL.C6	10	0.878	0.053	20100205.ST.SU	SU.C6	10	0.492	0.087
20091209.ER.SL	SL.C7	20	0.9	0.035	20100205.ST.SU	SU.C7	20	0.313	0.043
20091209.ER.SU	ER.C1	0.3125	1.022	0.046	20100208.AG.AK	AG.AK.C1	AG.AK.C1	0.91	0.044
20091209.ER.SU	ER.C2	0.625	1.002	0.067	20100208.AG.AK	AG.AK.C2	AG.AK.C2	0.897	0.043
20091209.ER.SU	ER.C3	1.25	1.004	0.04	20100208.AG.AK	AG.AK.C3	AG.AK.C3	0.831	0.028
20091209.ER.SU	ER.C4	2.5	0.967	0.038	20100208.AG.AK	AG.AK.C4	AG.AK.C4	0.811	0.028

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091209.ER.SU	ER.C5	5	0.973	0.027	20100208.AG.AK	AG.AK.C5	AG.AK.C5	0.58	0.02
20091209.ER.SU	ER.C6	10	1.004	0.031	20100208.AG.AK	AG.AK.C6	AG.AK.C6	0.349	0.018
20091209.ER.SU	ER.C7	20	0.829	0.045	20100208.AG.AK	AG.AK.C7	AG.AK.C7	0.221	0.005
20091209.ER.SU	ER.SU.C1	ER.SU.C1	0.829	0.123	20100208.AG.AK	AG.C1	0.078125	1.059	0.083
20091209.ER.SU	ER.SU.C2	ER.SU.C2	0.837	0.081	20100208.AG.AK	AG.C2	0.15625	0.96	0.041
20091209.ER.SU	ER.SU.C3	ER.SU.C3	0.739	0.078	20100208.AG.AK	AG.C3	0.3125	0.952	0.051
20091209.ER.SU	ER.SU.C4	ER.SU.C4	0.625	0.068	20100208.AG.AK	AG.C4	0.625	0.918	0.038
20091209.ER.SU	ER.SU.C5	ER.SU.C5	0.532	0.045	20100208.AG.AK	AG.C5	1.25	0.795	0.05
20091209.ER.SU	ER.SU.C6	ER.SU.C6	0.385	0.022	20100208.AG.AK	AG.C6	2.5	0.767	0.035
20091209.ER.SU	ER.SU.C7	ER.SU.C7	0.279	0.038	20100208.AG.AK	AG.C7	5	0.797	0.065
20091209.ER.SU	SU.C1	0.3125	0.978	0.145	20100208.AG.AK	AK.C1	0.3125	0.984	0.054
20091209.ER.SU	SU.C2	0.625	0.797	0.087	20100208.AG.AK	AK.C2	0.625	0.909	0.032
20091209.ER.SU	SU.C3	1.25	0.909	0.103	20100208.AG.AK	AK.C3	1.25	0.934	0.047
20091209.ER.SU	SU.C4	2.5	0.73	0.057	20100208.AG.AK	AK.C4	2.5	0.862	0.048
20091209.ER.SU	SU.C5	5	0.553	0.043	20100208.AG.AK	AK.C5	5	0.647	0.059
20091209.ER.SU	SU.C6	10	0.44	0.029	20100208.AG.AK	AK.C6	10	0.343	0.023
20091209.ER.SU	SU.C7	20	0.293	0.032	20100208.AG.AK	AK.C7	20	0.224	0.009
20091209.SL.SU	SL.C1	0.3125	1.311	0.091	20100208.AG.PD	AG.C1	0.078125	1.059	0.083
20091209.SL.SU	SL.C2	0.625	1.133	0.216	20100208.AG.PD	AG.C2	0.15625	0.96	0.041
20091209.SL.SU	SL.C3	1.25	1.03	0.152	20100208.AG.PD	AG.C3	0.3125	0.952	0.051
20091209.SL.SU	SL.C4	2.5	0.898	0.068	20100208.AG.PD	AG.C4	0.625	0.918	0.038
20091209.SL.SU	SL.C5	5	0.904	0.045	20100208.AG.PD	AG.C5	1.25	0.795	0.05
20091209.SL.SU	SL.C6	10	0.878	0.053	20100208.AG.PD	AG.C6	2.5	0.767	0.035
20091209.SL.SU	SL.C7	20	0.9	0.035	20100208.AG.PD	AG.C7	5	0.797	0.065
20091209.SL.SU	SL.SU.C1	SL.SU.C1	0.828	0.082	20100208.AG.PD	AG.PD.C1	AG.PD.C1	1.008	0.04
20091209.SL.SU	SL.SU.C2	SL.SU.C2	0.845	0.052	20100208.AG.PD	AG.PD.C2	AG.PD.C2	0.94	0.057
20091209.SL.SU	SL.SU.C3	SL.SU.C3	0.771	0.08	20100208.AG.PD	AG.PD.C3	AG.PD.C3	0.912	0.064
20091209.SL.SU	SL.SU.C4	SL.SU.C4	0.674	0.046	20100208.AG.PD	AG.PD.C4	AG.PD.C4	0.757	0.085
20091209.SL.SU	SL.SU.C5	SL.SU.C5	0.65	0.09	20100208.AG.PD	AG.PD.C5	AG.PD.C5	0.569	0.033
20091209.SL.SU	SL.SU.C6	SL.SU.C6	0.426	0.054	20100208.AG.PD	AG.PD.C6	AG.PD.C6	0.449	0.05
20091209.SL.SU	SL.SU.C7	SL.SU.C7	0.321	0.384	20100208.AG.PD	AG.PD.C7	AG.PD.C7	0.303	0.02
20091209.SL.SU	SU.C1	0.3125	0.978	0.145	20100208.AG.PD	PD.C1	0.15625	0.991	0.02
20091209.SL.SU	SU.C2	0.625	0.797	0.087	20100208.AG.PD	PD.C2	0.3125	0.954	0.048
20091209.SL.SU	SU.C3	1.25	0.909	0.103	20100208.AG.PD	PD.C3	0.625	0.846	0.04
20091209.SL.SU	SU.C4	2.5	0.73	0.057	20100208.AG.PD	PD.C4	1.25	0.83	0.038
20091209.SL.SU	SU.C5	5	0.553	0.043	20100208.AG.PD	PD.C5	2.5	0.641	0.03
20091209.SL.SU	SU.C6	10	0.44	0.029	20100208.AG.PD	PD.C6	5	0.402	0.015
20091209.SL.SU	SU.C7	20	0.293	0.032	20100208.AG.PD	PD.C7	10	0.26	0.042
20091211.AG.RT	AG.C1	0.3125	1.076	0.051	20100208.AG.SL	AG.C1	0.078125	1.059	0.083
20091211.AG.RT	AG.C2	0.625	0.964	0.076	20100208.AG.SL	AG.C2	0.15625	0.96	0.041
20091211.AG.RT	AG.C3	1.25	0.925	0.085	20100208.AG.SL	AG.C3	0.3125	0.952	0.051
20091211.AG.RT	AG.C4	2.5	0.813	0.044	20100208.AG.SL	AG.C4	0.625	0.918	0.038
20091211.AG.RT	AG.C5	5	0.842	0.058	20100208.AG.SL	AG.C5	1.25	0.795	0.05
20091211.AG.RT	AG.C6	10	0.8	0.035	20100208.AG.SL	AG.C6	2.5	0.767	0.035
20091211.AG.RT	AG.C7	20	0.667	0.061	20100208.AG.SL	AG.C7	5	0.797	0.065
20091211.AG.RT	AG.RT.C1	AG.RT.C1	0.957	0.085	20100208.AG.SL	AG.SL.C1	AG.SL.C1	1.145	0.086
20091211.AG.RT	AG.RT.C2	AG.RT.C2	0.941	0.059	20100208.AG.SL	AG.SL.C2	AG.SL.C2	1.158	0.098
20091211.AG.RT	AG.RT.C3	AG.RT.C3	0.886	0.061	20100208.AG.SL	AG.SL.C3	AG.SL.C3	0.969	0.075
20091211.AG.RT	AG.RT.C4	AG.RT.C4	0.616	0.056	20100208.AG.SL	AG.SL.C4	AG.SL.C4	0.807	0.121
20091211.AG.RT	AG.RT.C5	AG.RT.C5	0.518	0.038	20100208.AG.SL	AG.SL.C5	AG.SL.C5	0.744	0.069
20091211.AG.RT	AG.RT.C6	AG.RT.C6	0.177	0.011	20100208.AG.SL	AG.SL.C6	AG.SL.C6	0.633	0.062
20091211.AG.RT	AG.RT.C7	AG.RT.C7	0.104	0.009	20100208.AG.SL	AG.SL.C7	AG.SL.C7	0.601	0.052
20091211.AG.RT	RT.C1	0.0625	0.985	0.063	20100208.AG.SL	SL.C1	0.078125	1.193	0.034
20091211.AG.RT	RT.C2	0.125	0.919	0.048	20100208.AG.SL	SL.C2	0.15625	1.05	0.028
20091211.AG.RT	RT.C3	0.25	0.842	0.038	20100208.AG.SL	SL.C3	0.3125	1.117	0.047
20091211.AG.RT	RT.C4	0.5	0.745	0.054	20100208.AG.SL	SL.C4	0.625	1.019	0.027
20091211.AG.RT	RT.C5	1	0.687	0.034	20100208.AG.SL	SL.C5	1.25	0.904	0.037
20091211.AG.RT	RT.C6	2	0.198	0.022	20100208.AG.SL	SL.C6	2.5	0.807	0.075
20091211.AG.RT	RT.C7	4	0.138	0.01	20100208.AG.SL	SL.C7	5	0.647	0.036
20091211.AG.RY	AG.C1	0.3125	1.076	0.051	20100208.AK.PD	AK.C1	0.3125	0.984	0.054
20091211.AG.RY	AG.C2	0.625	0.964	0.076	20100208.AK.PD	AK.C2	0.625	0.909	0.032
20091211.AG.RY	AG.C3	1.25	0.925	0.085	20100208.AK.PD	AK.C3	1.25	0.934	0.047
20091211.AG.RY	AG.C4	2.5	0.813	0.044	20100208.AK.PD	AK.C4	2.5	0.862	0.048
20091211.AG.RY	AG.C5	5	0.842	0.058	20100208.AK.PD	AK.C5	5	0.647	0.059
20091211.AG.RY	AG.C6	10	0.8	0.035	20100208.AK.PD	AK.C6	10	0.343	0.023
20091211.AG.RY	AG.C7	20	0.667	0.061	20100208.AK.PD	AK.C7	20	0.224	0.009
20091211.AG.RY	AG.RY.C1	AG.RY.C1	1.15	0.039	20100208.AK.PD	AK.PD.C1	AK.PD.C1	0.881	0.021
20091211.AG.RY	AG.RY.C2	AG.RY.C2	1.067	0.048	20100208.AK.PD	AK.PD.C2	AK.PD.C2	0.817	0.071
20091211.AG.RY	AG.RY.C3	AG.RY.C3	1.07	0.03	20100208.AK.PD	AK.PD.C3	AK.PD.C3	0.733	0.09

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091211.AG.RY	AG.RY.C4	AG.RY.C4	1.045	0.048	20100208.AK.PD	AK.PD.C4	AK.PD.C4	0.563	0.045
20091211.AG.RY	AG.RY.C5	AG.RY.C5	0.923	0.02	20100208.AK.PD	AK.PD.C5	AK.PD.C5	0.438	0.055
20091211.AG.RY	AG.RY.C6	AG.RY.C6	0.387	0.031	20100208.AK.PD	AK.PD.C6	AK.PD.C6	0.242	0.022
20091211.AG.RY	AG.RY.C7	AG.RY.C7	0.037	0.002	20100208.AK.PD	AK.PD.C7	AK.PD.C7	0.157	0.012
20091211.AG.RY	RY.C1	0.03125	1.098	0.035	20100208.AK.PD	PD.C1	0.15625	0.991	0.02
20091211.AG.RY	RY.C2	0.0625	0.989	0.09	20100208.AK.PD	PD.C2	0.3125	0.954	0.048
20091211.AG.RY	RY.C3	0.125	0.992	0.05	20100208.AK.PD	PD.C3	0.625	0.846	0.04
20091211.AG.RY	RY.C4	0.25	1.036	0.015	20100208.AK.PD	PD.C4	1.25	0.83	0.038
20091211.AG.RY	RY.C5	0.5	1.003	0.043	20100208.AK.PD	PD.C5	2.5	0.641	0.03
20091211.AG.RY	RY.C6	1	0.724	0.027	20100208.AK.PD	PD.C6	5	0.402	0.015
20091211.AG.RY	RY.C7	2	0.089	0.031	20100208.AK.PD	PD.C7	10	0.26	0.042
20091211.AG.ST	AG.C1	0.3125	1.076	0.051	20100208.AK.SL	AK.C1	0.3125	0.984	0.054
20091211.AG.ST	AG.C2	0.625	0.964	0.076	20100208.AK.SL	AK.C2	0.625	0.909	0.032
20091211.AG.ST	AG.C3	1.25	0.925	0.085	20100208.AK.SL	AK.C3	1.25	0.934	0.047
20091211.AG.ST	AG.C4	2.5	0.813	0.044	20100208.AK.SL	AK.C4	2.5	0.862	0.048
20091211.AG.ST	AG.C5	5	0.842	0.058	20100208.AK.SL	AK.C5	5	0.647	0.059
20091211.AG.ST	AG.C6	10	0.8	0.035	20100208.AK.SL	AK.C6	10	0.343	0.023
20091211.AG.ST	AG.C7	20	0.667	0.061	20100208.AK.SL	AK.C7	20	0.224	0.009
20091211.AG.ST	AG.ST.C1	AG.ST.C1	0.703	0.024	20100208.AK.SL	AK.SL.C1	AK.SL.C1	0.969	0.036
20091211.AG.ST	AG.ST.C2	AG.ST.C2	0.923	0.022	20100208.AK.SL	AK.SL.C2	AK.SL.C2	0.879	0.039
20091211.AG.ST	AG.ST.C3	AG.ST.C3	0.868	0.044	20100208.AK.SL	AK.SL.C3	AK.SL.C3	0.857	0.026
20091211.AG.ST	AG.ST.C4	AG.ST.C4	0.848	0.038	20100208.AK.SL	AK.SL.C4	AK.SL.C4	0.673	0.058
20091211.AG.ST	AG.ST.C5	AG.ST.C5	0.82	0.039	20100208.AK.SL	AK.SL.C5	AK.SL.C5	0.554	0.046
20091211.AG.ST	AG.ST.C6	AG.ST.C6	0.654	0.1	20100208.AK.SL	AK.SL.C6	AK.SL.C6	0.331	0.029
20091211.AG.ST	AG.ST.C7	AG.ST.C7	0.285	0.056	20100208.AK.SL	AK.SL.C7	AK.SL.C7	0.214	0.017
20091211.AG.ST	ST.C1	0.00625	1.145	0.102	20100208.AK.SL	SL.C1	0.078125	1.193	0.034
20091211.AG.ST	ST.C2	0.0125	1.107	0.018	20100208.AK.SL	SL.C2	0.15625	1.05	0.028
20091211.AG.ST	ST.C3	0.025	1.089	0.052	20100208.AK.SL	SL.C3	0.3125	1.117	0.047
20091211.AG.ST	ST.C4	0.05	1.053	0.077	20100208.AK.SL	SL.C4	0.625	1.019	0.027
20091211.AG.ST	ST.C5	0.1	1.114	0.052	20100208.AK.SL	SL.C5	1.25	0.904	0.037
20091211.AG.ST	ST.C6	0.2	1.072	0.049	20100208.AK.SL	SL.C6	2.5	0.807	0.075
20091211.AG.ST	ST.C7	0.4	0.738	0.044	20100208.AK.SL	SL.C7	5	0.647	0.036
20091211.RT.RY	RT.C1	0.0625	0.985	0.063	20100208.AK.SR	AK.C1	0.3125	0.984	0.054
20091211.RT.RY	RT.C2	0.125	0.919	0.048	20100208.AK.SR	AK.C2	0.625	0.909	0.032
20091211.RT.RY	RT.C3	0.25	0.842	0.038	20100208.AK.SR	AK.C3	1.25	0.934	0.047
20091211.RT.RY	RT.C4	0.5	0.745	0.054	20100208.AK.SR	AK.C4	2.5	0.862	0.048
20091211.RT.RY	RT.C5	1	0.687	0.034	20100208.AK.SR	AK.C5	5	0.647	0.059
20091211.RT.RY	RT.C6	2	0.198	0.022	20100208.AK.SR	AK.C6	10	0.343	0.023
20091211.RT.RY	RT.C7	4	0.138	0.01	20100208.AK.SR	AK.C7	20	0.224	0.009
20091211.RT.RY	RT.RY.C1	RT.RY.C1	1.094	0.055	20100208.AK.SR	AK.SR.C1	AK.SR.C1	1.058	0.03
20091211.RT.RY	RT.RY.C2	RT.RY.C2	1.097	0.034	20100208.AK.SR	AK.SR.C2	AK.SR.C2	1.031	0.034
20091211.RT.RY	RT.RY.C3	RT.RY.C3	1.062	0.033	20100208.AK.SR	AK.SR.C3	AK.SR.C3	0.984	0.041
20091211.RT.RY	RT.RY.C4	RT.RY.C4	1.207	0.028	20100208.AK.SR	AK.SR.C4	AK.SR.C4	0.91	0.064
20091211.RT.RY	RT.RY.C5	RT.RY.C5	0.998	0.068	20100208.AK.SR	AK.SR.C5	AK.SR.C5	0.656	0.044
20091211.RT.RY	RT.RY.C6	RT.RY.C6	0.155	0.037	20100208.AK.SR	AK.SR.C6	AK.SR.C6	0.378	0.023
20091211.RT.RY	RT.RY.C7	RT.RY.C7	0.027	0.004	20100208.AK.SR	AK.SR.C7	AK.SR.C7	0.162	0.015
20091211.RT.RY	RY.C1	0.03125	1.098	0.035	20100208.AK.SR	SR.C1	0.078125	1.099	0.036
20091211.RT.RY	RY.C2	0.0625	0.989	0.09	20100208.AK.SR	SR.C2	0.15625	1.106	0.037
20091211.RT.RY	RY.C3	0.125	0.992	0.05	20100208.AK.SR	SR.C3	0.3125	0.96	0.099
20091211.RT.RY	RY.C4	0.25	1.036	0.015	20100208.AK.SR	SR.C4	0.625	1.047	0.077
20091211.RT.RY	RY.C5	0.5	1.003	0.043	20100208.AK.SR	SR.C5	1.25	0.981	0.082
20091211.RT.RY	RY.C6	1	0.724	0.027	20100208.AK.SR	SR.C6	2.5	1.035	0.055
20091211.RT.RY	RY.C7	2	0.089	0.031	20100208.AK.SR	SR.C7	5	0.981	0.094
20091211.RT.ST	RT.C1	0.0625	0.985	0.063	20100208.PD.SL	PD.C1	0.15625	0.991	0.02
20091211.RT.ST	RT.C2	0.125	0.919	0.048	20100208.PD.SL	PD.C2	0.3125	0.954	0.048
20091211.RT.ST	RT.C3	0.25	0.842	0.038	20100208.PD.SL	PD.C3	0.625	0.846	0.04
20091211.RT.ST	RT.C4	0.5	0.745	0.054	20100208.PD.SL	PD.C4	1.25	0.83	0.038
20091211.RT.ST	RT.C5	1	0.687	0.034	20100208.PD.SL	PD.C5	2.5	0.641	0.03
20091211.RT.ST	RT.C6	2	0.198	0.022	20100208.PD.SL	PD.C6	5	0.402	0.015
20091211.RT.ST	RT.C7	4	0.138	0.01	20100208.PD.SL	PD.C7	10	0.26	0.042
20091211.RT.ST	RT.ST.C1	RT.ST.C1	1.044	0.034	20100208.PD.SL	PD.SL.C1	PD.SL.C1	0.942	0.05
20091211.RT.ST	RT.ST.C2	RT.ST.C2	1.009	0.04	20100208.PD.SL	PD.SL.C2	PD.SL.C2	0.926	0.044
20091211.RT.ST	RT.ST.C3	RT.ST.C3	0.974	0.06	20100208.PD.SL	PD.SL.C3	PD.SL.C3	0.812	0.031
20091211.RT.ST	RT.ST.C4	RT.ST.C4	0.915	0.044	20100208.PD.SL	PD.SL.C4	PD.SL.C4	0.674	0.032
20091211.RT.ST	RT.ST.C5	RT.ST.C5	0.719	0.029	20100208.PD.SL	PD.SL.C5	PD.SL.C5	0.519	0.031
20091211.RT.ST	RT.ST.C6	RT.ST.C6	0.205	0.018	20100208.PD.SL	PD.SL.C6	PD.SL.C6	0.345	0.03
20091211.RT.ST	RT.ST.C7	RT.ST.C7	0.145	0.014	20100208.PD.SL	PD.SL.C7	PD.SL.C7	0.206	0.012
20091211.RT.ST	ST.C1	0.00625	1.145	0.102	20100208.PD.SL	SL.C1	0.078125	1.193	0.034
20091211.RT.ST	ST.C2	0.0125	1.107	0.018	20100208.PD.SL	SL.C2	0.15625	1.05	0.028

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091211.RT.ST	ST.C3	0.025	1.089	0.052	20100208.PD.SL	SL.C3	0.3125	1.117	0.047
20091211.RT.ST	ST.C4	0.05	1.053	0.077	20100208.PD.SL	SL.C4	0.625	1.019	0.027
20091211.RT.ST	ST.C5	0.1	1.114	0.052	20100208.PD.SL	SL.C5	1.25	0.904	0.037
20091211.RT.ST	ST.C6	0.2	1.072	0.049	20100208.PD.SL	SL.C6	2.5	0.807	0.075
20091211.RT.ST	ST.C7	0.4	0.738	0.044	20100208.PD.SL	SL.C7	5	0.647	0.036
20091211.RY.ST	RY.C1	0.03125	1.098	0.035	20100208.PD.SR	PD.C1	0.15625	0.991	0.02
20091211.RY.ST	RY.C2	0.0625	0.989	0.09	20100208.PD.SR	PD.C2	0.3125	0.954	0.048
20091211.RY.ST	RY.C3	0.125	0.992	0.05	20100208.PD.SR	PD.C3	0.625	0.846	0.04
20091211.RY.ST	RY.C4	0.25	1.036	0.015	20100208.PD.SR	PD.C4	1.25	0.83	0.038
20091211.RY.ST	RY.C5	0.5	1.003	0.043	20100208.PD.SR	PD.C5	2.5	0.641	0.03
20091211.RY.ST	RY.C6	1	0.724	0.027	20100208.PD.SR	PD.C6	5	0.402	0.015
20091211.RY.ST	RY.C7	2	0.089	0.031	20100208.PD.SR	PD.C7	10	0.26	0.042
20091211.RY.ST	RY.ST.C1	RY.ST.C1	1.009	0.041	20100208.PD.SR	PD.SR.C1	PD.SR.C1	0.922	0.052
20091211.RY.ST	RY.ST.C2	RY.ST.C2	1.041	0.053	20100208.PD.SR	PD.SR.C2	PD.SR.C2	0.937	0.054
20091211.RY.ST	RY.ST.C3	RY.ST.C3	0.945	0.058	20100208.PD.SR	PD.SR.C3	PD.SR.C3	0.878	0.056
20091211.RY.ST	RY.ST.C4	RY.ST.C4	1.003	0.048	20100208.PD.SR	PD.SR.C4	PD.SR.C4	0.783	0.047
20091211.RY.ST	RY.ST.C5	RY.ST.C5	0.989	0.017	20100208.PD.SR	PD.SR.C5	PD.SR.C5	0.618	0.054
20091211.RY.ST	RY.ST.C6	RY.ST.C6	0.572	0.062	20100208.PD.SR	PD.SR.C6	PD.SR.C6	0.397	0.034
20091211.RY.ST	RY.ST.C7	RY.ST.C7	0.02	0.012	20100208.PD.SR	PD.SR.C7	PD.SR.C7	0.263	0.014
20091211.RY.ST	ST.C1	0.00625	1.145	0.102	20100208.PD.SR	SR.C1	0.078125	1.099	0.036
20091211.RY.ST	ST.C2	0.0125	1.107	0.018	20100208.PD.SR	SR.C2	0.15625	1.106	0.037
20091211.RY.ST	ST.C3	0.025	1.089	0.052	20100208.PD.SR	SR.C3	0.3125	0.96	0.099
20091211.RY.ST	ST.C4	0.05	1.053	0.077	20100208.PD.SR	SR.C4	0.625	1.047	0.077
20091211.RY.ST	ST.C5	0.1	1.114	0.052	20100208.PD.SR	SR.C5	1.25	0.981	0.082
20091211.RY.ST	ST.C6	0.2	1.072	0.049	20100208.PD.SR	SR.C6	2.5	1.035	0.055
20091211.RY.ST	ST.C7	0.4	0.738	0.044	20100208.PD.SR	SR.C7	5	0.981	0.094
20091215.AK.RY	AK.C1	0.3125	0.951	0.028	20100208.SL.SR	SL.C1	0.078125	1.193	0.034
20091215.AK.RY	AK.C2	0.625	0.935	0.035	20100208.SL.SR	SL.C2	0.15625	1.05	0.028
20091215.AK.RY	AK.C3	1.25	0.878	0.047	20100208.SL.SR	SL.C3	0.3125	1.117	0.047
20091215.AK.RY	AK.C4	2.5	0.803	0.024	20100208.SL.SR	SL.C4	0.625	1.019	0.027
20091215.AK.RY	AK.C5	5	0.674	0.066	20100208.SL.SR	SL.C5	1.25	0.904	0.037
20091215.AK.RY	AK.C6	10	0.33	0.024	20100208.SL.SR	SL.C6	2.5	0.807	0.075
20091215.AK.RY	AK.C7	20	0.217	0.012	20100208.SL.SR	SL.C7	5	0.647	0.036
20091215.AK.RY	AK.RY.C1	AK.RY.C1	0.884	0.006	20100208.SL.SR	SL.SR.C1	SL.SR.C1	0.974	0.042
20091215.AK.RY	AK.RY.C2	AK.RY.C2	0.874	0.046	20100208.SL.SR	SL.SR.C2	SL.SR.C2	1.02	0.085
20091215.AK.RY	AK.RY.C3	AK.RY.C3	0.832	0.016	20100208.SL.SR	SL.SR.C3	SL.SR.C3	0.977	0.061
20091215.AK.RY	AK.RY.C4	AK.RY.C4	0.823	0.031	20100208.SL.SR	SL.SR.C4	SL.SR.C4	0.91	0.019
20091215.AK.RY	AK.RY.C5	AK.RY.C5	0.529	0.068	20100208.SL.SR	SL.SR.C5	SL.SR.C5	0.827	0.038
20091215.AK.RY	AK.RY.C6	AK.RY.C6	0.198	0.017	20100208.SL.SR	SL.SR.C6	SL.SR.C6	0.782	0.058
20091215.AK.RY	AK.RY.C7	AK.RY.C7	0.012	0.001	20100208.SL.SR	SL.SR.C7	SL.SR.C7	0.553	0.027
20091215.AK.RY	RY.C1	0.03125	0.941	0.04	20100208.SL.SR	SR.C1	0.078125	1.099	0.036
20091215.AK.RY	RY.C2	0.0625	0.975	0.044	20100208.SL.SR	SR.C2	0.15625	1.106	0.037
20091215.AK.RY	RY.C3	0.125	0.959	0.018	20100208.SL.SR	SR.C3	0.3125	0.96	0.099
20091215.AK.RY	RY.C4	0.25	0.929	0.04	20100208.SL.SR	SR.C4	0.625	1.047	0.077
20091215.AK.RY	RY.C5	0.5	0.964	0.045	20100208.SL.SR	SR.C5	1.25	0.981	0.082
20091215.AK.RY	RY.C6	1	0.681	0.048	20100208.SL.SR	SR.C6	2.5	1.035	0.055
20091215.AK.RY	RY.C7	2	0.117	0.02	20100208.SL.SR	SR.C7	5	0.981	0.094
20091221.AG.HN	AG.C1	0.078125	0.958	0.037	20100212.ER.HN	ER.C1	0.078125	1	0.029
20091221.AG.HN	AG.C2	0.15625	1.044	0.1	20100212.ER.HN	ER.C2	0.15625	0.942	0.055
20091221.AG.HN	AG.C3	0.3125	0.976	0.026	20100212.ER.HN	ER.C3	0.3125	0.951	0.027
20091221.AG.HN	AG.C4	0.625	0.979	0.078	20100212.ER.HN	ER.C4	0.625	0.922	0.041
20091221.AG.HN	AG.C5	1.25	0.945	0.063	20100212.ER.HN	ER.C5	1.25	0.931	0.037
20091221.AG.HN	AG.C6	2.5	0.827	0.066	20100212.ER.HN	ER.C6	2.5	0.924	0.032
20091221.AG.HN	AG.C7	5	0.857	0.078	20100212.ER.HN	ER.C7	5	0.965	0.079
20091221.AG.HN	AG.HN.C1	AG.HN.C1	0.955	0.056	20100212.ER.HN	ER.HN.C1	ER.HN.C1	0.957	0.057
20091221.AG.HN	AG.HN.C2	AG.HN.C2	0.933	0.048	20100212.ER.HN	ER.HN.C2	ER.HN.C2	0.851	0.036
20091221.AG.HN	AG.HN.C3	AG.HN.C3	0.809	0.03	20100212.ER.HN	ER.HN.C3	ER.HN.C3	0.908	0.054
20091221.AG.HN	AG.HN.C4	AG.HN.C4	0.756	0.049	20100212.ER.HN	ER.HN.C4	ER.HN.C4	0.707	0.04
20091221.AG.HN	AG.HN.C5	AG.HN.C5	0.606	0.023	20100212.ER.HN	ER.HN.C5	ER.HN.C5	0.57	0.039
20091221.AG.HN	AG.HN.C6	AG.HN.C6	0.234	0.013	20100212.ER.HN	ER.HN.C6	ER.HN.C6	0.28	0.021
20091221.AG.HN	AG.HN.C7	AG.HN.C7	0.055	0.009	20100212.ER.HN	ER.HN.C7	ER.HN.C7	0.049	0.004
20091221.AG.HN	HN.C1	0.3125	1	0.074	20100212.ER.HN	HN.C1	0.3125	0.993	0.063
20091221.AG.HN	HN.C2	0.625	0.907	0.08	20100212.ER.HN	HN.C2	0.625	1.105	0.064
20091221.AG.HN	HN.C3	1.25	0.833	0.059	20100212.ER.HN	HN.C3	1.25	0.998	0.045
20091221.AG.HN	HN.C4	2.5	0.779	0.072	20100212.ER.HN	HN.C4	2.5	0.927	0.133
20091221.AG.HN	HN.C5	5	0.642	0.084	20100212.ER.HN	HN.C5	5	0.672	0.122
20091221.AG.HN	HN.C6	10	0.296	0.046	20100212.ER.HN	HN.C6	10	0.398	0.124
20091221.AG.HN	HN.C7	20	0.058	0.014	20100212.ER.HN	HN.C7	20	0.069	0.028
20091221.AG.SL	AG.C1	0.078125	0.958	0.037	20100212.GF.PI	GF.C1	0.3125	1.047	0.081

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091221.AG.SL	AG.C2	0.15625	1.044	0.1	20100212.GF.PI	GF.C2	0.625	0.961	0.045
20091221.AG.SL	AG.C3	0.3125	0.976	0.026	20100212.GF.PI	GF.C3	1.25	0.938	0.041
20091221.AG.SL	AG.C4	0.625	0.979	0.078	20100212.GF.PI	GF.C4	2.5	0.86	0.053
20091221.AG.SL	AG.C5	1.25	0.945	0.063	20100212.GF.PI	GF.C5	5	0.62	0.039
20091221.AG.SL	AG.C6	2.5	0.827	0.066	20100212.GF.PI	GF.C6	10	0.421	0.017
20091221.AG.SL	AG.C7	5	0.857	0.078	20100212.GF.PI	GF.C7	20	0.133	0.006
20091221.AG.SL	AG.SL.C1	AG.SL.C1	0.942	0.05	20100212.GF.PI	GF.PI.C1	GF.PI.C1	0.822	0.083
20091221.AG.SL	AG.SL.C2	AG.SL.C2	0.877	0.028	20100212.GF.PI	GF.PI.C2	GF.PI.C2	0.784	0.065
20091221.AG.SL	AG.SL.C3	AG.SL.C3	0.815	0.045	20100212.GF.PI	GF.PI.C3	GF.PI.C3	0.542	0.042
20091221.AG.SL	AG.SL.C4	AG.SL.C4	0.696	0.034	20100212.GF.PI	GF.PI.C4	GF.PI.C4	0.422	0.021
20091221.AG.SL	AG.SL.C5	AG.SL.C5	0.427	0.045	20100212.GF.PI	GF.PI.C5	GF.PI.C5	0.274	0.014
20091221.AG.SL	AG.SL.C6	AG.SL.C6	0.322	0.03	20100212.GF.PI	GF.PI.C6	GF.PI.C6	0.13	0.014
20091221.AG.SL	AG.SL.C7	AG.SL.C7	0.216	0.018	20100212.GF.PI	GF.PI.C7	GF.PI.C7	0.044	0.002
20091221.AG.SL	SL.C1	0.078125	1.019	0.03	20100212.GF.PI	PI.C1	0.0625	0.955	0.013
20091221.AG.SL	SL.C2	0.15625	1.005	0.035	20100212.GF.PI	PI.C2	0.125	0.867	0.036
20091221.AG.SL	SL.C3	0.3125	1.017	0.046	20100212.GF.PI	PI.C3	0.25	0.653	0.048
20091221.AG.SL	SL.C4	0.625	1.019	0.031	20100212.GF.PI	PI.C4	0.5	0.529	0.023
20091221.AG.SL	SL.C5	1.25	0.904	0.044	20100212.GF.PI	PI.C5	1	0.368	0.014
20091221.AG.SL	SL.C6	2.5	0.966	0.035	20100212.GF.PI	PI.C6	2	0.27	0.017
20091221.AG.SL	SL.C7	5	0.903	0.049	20100212.GF.PI	PI.C7	4	0.199	0.004
20091221.HN.PI	HN.C1	0.3125	1	0.074	20100212.GF.RT	GF.C1	0.3125	1.047	0.081
20091221.HN.PI	HN.C2	0.625	0.907	0.08	20100212.GF.RT	GF.C2	0.625	0.961	0.045
20091221.HN.PI	HN.C3	1.25	0.833	0.059	20100212.GF.RT	GF.C3	1.25	0.938	0.041
20091221.HN.PI	HN.C4	2.5	0.779	0.072	20100212.GF.RT	GF.C4	2.5	0.86	0.053
20091221.HN.PI	HN.C5	5	0.642	0.084	20100212.GF.RT	GF.C5	5	0.62	0.039
20091221.HN.PI	HN.C6	10	0.296	0.046	20100212.GF.RT	GF.C6	10	0.421	0.017
20091221.HN.PI	HN.C7	20	0.058	0.014	20100212.GF.RT	GF.C7	20	0.133	0.006
20091221.HN.PI	HN.PI.C1	HN.PI.C1	1.177	0.064	20100212.GF.RT	GF.RT.C1	GF.RT.C1	0.963	0.029
20091221.HN.PI	HN.PI.C2	HN.PI.C2	1.026	0.044	20100212.GF.RT	GF.RT.C2	GF.RT.C2	0.988	0.043
20091221.HN.PI	HN.PI.C3	HN.PI.C3	0.931	0.031	20100212.GF.RT	GF.RT.C3	GF.RT.C3	0.93	0.024
20091221.HN.PI	HN.PI.C4	HN.PI.C4	0.845	0.043	20100212.GF.RT	GF.RT.C4	GF.RT.C4	0.873	0.026
20091221.HN.PI	HN.PI.C5	HN.PI.C5	0.549	0.016	20100212.GF.RT	GF.RT.C5	GF.RT.C5	0.686	0.078
20091221.HN.PI	HN.PI.C6	HN.PI.C6	0.376	0.022	20100212.GF.RT	GF.RT.C6	GF.RT.C6	0.385	0.03
20091221.HN.PI	HN.PI.C7	HN.PI.C7	0.263	0.015	20100212.GF.RT	GF.RT.C7	GF.RT.C7	0.106	0.006
20091221.HN.PI	PI.C1	0.0625	0.874	0.063	20100212.GF.RT	RT.C1	0.078125	1.053	0.043
20091221.HN.PI	PI.C2	0.125	0.775	0.077	20100212.GF.RT	RT.C2	0.15625	1.009	0.033
20091221.HN.PI	PI.C3	0.25	0.705	0.025	20100212.GF.RT	RT.C3	0.3125	0.971	0.041
20091221.HN.PI	PI.C4	0.5	0.628	0.027	20100212.GF.RT	RT.C4	0.625	0.939	0.054
20091221.HN.PI	PI.C5	1	0.453	0.025	20100212.GF.RT	RT.C5	1.25	0.945	0.049
20091221.HN.PI	PI.C6	2	0.295	0.031	20100212.GF.RT	RT.C6	2.5	0.808	0.033
20091221.HN.PI	PI.C7	4	0.218	0.007	20100212.GF.RT	RT.C7	5	0.672	0.09
20091221.HN.SL	HN.C1	0.3125	1	0.074	20100212.PI.RT	PI.C1	0.0625	0.955	0.013
20091221.HN.SL	HN.C2	0.625	0.907	0.08	20100212.PI.RT	PI.C2	0.125	0.867	0.036
20091221.HN.SL	HN.C3	1.25	0.833	0.059	20100212.PI.RT	PI.C3	0.25	0.653	0.048
20091221.HN.SL	HN.C4	2.5	0.779	0.072	20100212.PI.RT	PI.C4	0.5	0.529	0.023
20091221.HN.SL	HN.C5	5	0.642	0.084	20100212.PI.RT	PI.C5	1	0.368	0.014
20091221.HN.SL	HN.C6	10	0.296	0.046	20100212.PI.RT	PI.C6	2	0.27	0.017
20091221.HN.SL	HN.C7	20	0.058	0.014	20100212.PI.RT	PI.C7	4	0.199	0.004
20091221.HN.SL	HN.SL.C1	HN.SL.C1	0.994	0.039	20100212.PI.RT	PI.RT.C1	PI.RT.C1	0.925	0.034
20091221.HN.SL	HN.SL.C2	HN.SL.C2	0.929	0.053	20100212.PI.RT	PI.RT.C2	PI.RT.C2	0.855	0.049
20091221.HN.SL	HN.SL.C3	HN.SL.C3	0.885	0.068	20100212.PI.RT	PI.RT.C3	PI.RT.C3	0.635	0.07
20091221.HN.SL	HN.SL.C4	HN.SL.C4	0.8	0.05	20100212.PI.RT	PI.RT.C4	PI.RT.C4	0.501	0.034
20091221.HN.SL	HN.SL.C5	HN.SL.C5	0.616	0.031	20100212.PI.RT	PI.RT.C5	PI.RT.C5	0.382	0.017
20091221.HN.SL	HN.SL.C6	HN.SL.C6	0.293	0.033	20100212.PI.RT	PI.RT.C6	PI.RT.C6	0.193	0.018
20091221.HN.SL	HN.SL.C7	HN.SL.C7	0.044	0.003	20100212.PI.RT	PI.RT.C7	PI.RT.C7	0.084	0.009
20091221.HN.SL	SL.C1	0.078125	1.019	0.03	20100212.PI.RT	RT.C1	0.078125	1.053	0.043
20091221.HN.SL	SL.C2	0.15625	1.005	0.035	20100212.PI.RT	RT.C2	0.15625	1.009	0.033
20091221.HN.SL	SL.C3	0.3125	1.017	0.046	20100212.PI.RT	RT.C3	0.3125	0.971	0.041
20091221.HN.SL	SL.C4	0.625	1.019	0.031	20100212.PI.RT	RT.C4	0.625	0.939	0.054
20091221.HN.SL	SL.C5	1.25	0.904	0.044	20100212.PI.RT	RT.C5	1.25	0.945	0.049
20091221.HN.SL	SL.C6	2.5	0.966	0.035	20100212.PI.RT	RT.C6	2.5	0.808	0.033
20091221.HN.SL	SL.C7	5	0.903	0.049	20100212.PI.RT	RT.C7	5	0.672	0.09
20091221.HN.SR	HN.C1	0.3125	1	0.074	20100216.AG.SU	AG.C1	0.078125	1.229	0.129
20091221.HN.SR	HN.C2	0.625	0.907	0.08	20100216.AG.SU	AG.C2	0.15625	1.059	0.073
20091221.HN.SR	HN.C3	1.25	0.833	0.059	20100216.AG.SU	AG.C3	0.3125	1	0.029
20091221.HN.SR	HN.C4	2.5	0.779	0.072	20100216.AG.SU	AG.C4	0.625	0.949	0.031
20091221.HN.SR	HN.C5	5	0.642	0.084	20100216.AG.SU	AG.C5	1.25	0.922	0.04
20091221.HN.SR	HN.C6	10	0.296	0.046	20100216.AG.SU	AG.C6	2.5	0.905	0.057
20091221.HN.SR	HN.C7	20	0.058	0.014	20100216.AG.SU	AG.C7	5	0.866	0.067

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091221.HN.SR	HN.SR.C1	HN.SR.C1	1.005	0.064	20100216.AG.SU	AG.SU.C1	AG.SU.C1	1.14	0.045
20091221.HN.SR	HN.SR.C2	HN.SR.C2	0.995	0.045	20100216.AG.SU	AG.SU.C2	AG.SU.C2	1.126	0.045
20091221.HN.SR	HN.SR.C3	HN.SR.C3	0.972	0.052	20100216.AG.SU	AG.SU.C3	AG.SU.C3	1.11	0.029
20091221.HN.SR	HN.SR.C4	HN.SR.C4	0.86	0.053	20100216.AG.SU	AG.SU.C4	AG.SU.C4	0.95	0.073
20091221.HN.SR	HN.SR.C5	HN.SR.C5	0.685	0.049	20100216.AG.SU	AG.SU.C5	AG.SU.C5	0.658	0.32
20091221.HN.SR	HN.SR.C6	HN.SR.C6	0.332	0.021	20100216.AG.SU	AG.SU.C6	AG.SU.C6	0.578	0.013
20091221.HN.SR	HN.SR.C7	HN.SR.C7	0.094	0.011	20100216.AG.SU	AG.SU.C7	AG.SU.C7	0.355	0.018
20091221.HN.SR	SR.C1	0.078125	0.946	0.098	20100216.AG.SU	SU.C1	0.3125	1.171	0.114
20091221.HN.SR	SR.C2	0.15625	0.998	0.116	20100216.AG.SU	SU.C2	0.625	1.137	0.118
20091221.HN.SR	SR.C3	0.3125	1.069	0.123	20100216.AG.SU	SU.C3	1.25	1.058	0.041
20091221.HN.SR	SR.C4	0.625	1.089	0.115	20100216.AG.SU	SU.C4	2.5	0.818	0.05
20091221.HN.SR	SR.C5	1.25	1.058	0.12	20100216.AG.SU	SU.C5	5	0.605	0.059
20091221.HN.SR	SR.C6	2.5	1.093	0.121	20100216.AG.SU	SU.C6	10	0.575	0.026
20091221.HN.SR	SR.C7	5	1.044	0.156	20100216.AG.SU	SU.C7	20	0.316	0.025
20091221.PI.SL	PI.C1	0.0625	0.874	0.063	20100216.AK.HN	AK.C1	0.3125	0.96	0.089
20091221.PI.SL	PI.C2	0.125	0.775	0.077	20100216.AK.HN	AK.C2	0.625	0.808	0.062
20091221.PI.SL	PI.C3	0.25	0.705	0.025	20100216.AK.HN	AK.C3	1.25	0.831	0.087
20091221.PI.SL	PI.C4	0.5	0.628	0.027	20100216.AK.HN	AK.C4	2.5	0.746	0.024
20091221.PI.SL	PI.C5	1	0.453	0.025	20100216.AK.HN	AK.C5	5	0.609	0.064
20091221.PI.SL	PI.C6	2	0.295	0.031	20100216.AK.HN	AK.C6	10	0.365	0.021
20091221.PI.SL	PI.C7	4	0.218	0.007	20100216.AK.HN	AK.C7	20	0.193	0.016
20091221.PI.SL	PI.SL.C1	PI.SL.C1	0.976	0.029	20100216.AK.HN	AK.HN.C1	AK.HN.C1	0.893	0.03
20091221.PI.SL	PI.SL.C2	PI.SL.C2	0.925	0.065	20100216.AK.HN	AK.HN.C2	AK.HN.C2	0.897	0.038
20091221.PI.SL	PI.SL.C3	PI.SL.C3	0.717	0.062	20100216.AK.HN	AK.HN.C3	AK.HN.C3	0.826	0.028
20091221.PI.SL	PI.SL.C4	PI.SL.C4	0.523	0.009	20100216.AK.HN	AK.HN.C4	AK.HN.C4	0.748	0.042
20091221.PI.SL	PI.SL.C5	PI.SL.C5	0.345	0.011	20100216.AK.HN	AK.HN.C5	AK.HN.C5	0.511	0.015
20091221.PI.SL	PI.SL.C6	PI.SL.C6	0.151	0.009	20100216.AK.HN	AK.HN.C6	AK.HN.C6	0.288	0.013
20091221.PI.SL	PI.SL.C7	PI.SL.C7	0.05	0.003	20100216.AK.HN	AK.HN.C7	AK.HN.C7	0.006	0.001
20091221.PI.SL	SL.C1	0.078125	1.019	0.03	20100216.AK.HN	HN.C1	0.3125	1.203	0.067
20091221.PI.SL	SL.C2	0.15625	1.005	0.035	20100216.AK.HN	HN.C2	0.625	1.033	0.125
20091221.PI.SL	SL.C3	0.3125	1.017	0.046	20100216.AK.HN	HN.C3	1.25	0.967	0.092
20091221.PI.SL	SL.C4	0.625	1.019	0.031	20100216.AK.HN	HN.C4	2.5	0.773	0.073
20091221.PI.SL	SL.C5	1.25	0.904	0.044	20100216.AK.HN	HN.C5	5	0.511	0.038
20091221.PI.SL	SL.C6	2.5	0.966	0.035	20100216.AK.HN	HN.C6	10	0.256	0.027
20091221.PI.SL	SL.C7	5	0.903	0.049	20100216.AK.HN	HN.C7	20	0.013	0.003
20091221.PI.SR	PI.C1	0.0625	0.874	0.063	20100216.ER.SR	ER.C1	0.078125	1.184	0.037
20091221.PI.SR	PI.C2	0.125	0.775	0.077	20100216.ER.SR	ER.C2	0.15625	1.136	0.024
20091221.PI.SR	PI.C3	0.25	0.705	0.025	20100216.ER.SR	ER.C3	0.3125	1.128	0.085
20091221.PI.SR	PI.C4	0.5	0.628	0.027	20100216.ER.SR	ER.C4	0.625	1.099	0.085
20091221.PI.SR	PI.C5	1	0.453	0.025	20100216.ER.SR	ER.C5	1.25	1.024	0.123
20091221.PI.SR	PI.C6	2	0.295	0.031	20100216.ER.SR	ER.C6	2.5	1.074	0.094
20091221.PI.SR	PI.C7	4	0.218	0.007	20100216.ER.SR	ER.C7	5	0.975	0.045
20091221.PI.SR	PI.SR.C1	PI.SR.C1	1.045	0.042	20100216.ER.SR	ER.SR.C1	ER.SR.C1	1.17	0.087
20091221.PI.SR	PI.SR.C2	PI.SR.C2	1.017	0.091	20100216.ER.SR	ER.SR.C2	ER.SR.C2	1.137	0.062
20091221.PI.SR	PI.SR.C3	PI.SR.C3	0.822	0.035	20100216.ER.SR	ER.SR.C3	ER.SR.C3	1.208	0.076
20091221.PI.SR	PI.SR.C4	PI.SR.C4	0.589	0.026	20100216.ER.SR	ER.SR.C4	ER.SR.C4	1.206	0.066
20091221.PI.SR	PI.SR.C5	PI.SR.C5	0.453	0.036	20100216.ER.SR	ER.SR.C5	ER.SR.C5	1.21	0.06
20091221.PI.SR	PI.SR.C6	PI.SR.C6	0.32	0.023	20100216.ER.SR	ER.SR.C6	ER.SR.C6	1.169	0.093
20091221.PI.SR	PI.SR.C7	PI.SR.C7	0.264	0.018	20100216.ER.SR	ER.SR.C7	ER.SR.C7	0.979	0.101
20091221.PI.SR	SR.C1	0.078125	0.946	0.098	20100216.ER.SR	SR.C1	0.078125	1.15	0.052
20091221.PI.SR	SR.C2	0.15625	0.998	0.116	20100216.ER.SR	SR.C2	0.15625	1.164	0.051
20091221.PI.SR	SR.C3	0.3125	1.069	0.123	20100216.ER.SR	SR.C3	0.3125	1.137	0.056
20091221.PI.SR	SR.C4	0.625	1.089	0.115	20100216.ER.SR	SR.C4	0.625	1.172	0.083
20091221.PI.SR	SR.C5	1.25	1.058	0.12	20100216.ER.SR	SR.C5	1.25	1.108	0.066
20091221.PI.SR	SR.C6	2.5	1.093	0.121	20100216.ER.SR	SR.C6	2.5	1.166	0.057
20091221.PI.SR	SR.C7	5	1.044	0.156	20100216.ER.SR	SR.C7	5	1.019	0.059
20091221.SL.SR	SL.C1	0.078125	1.019	0.03	20100216.HN.PD	HN.C1	0.3125	1.203	0.067
20091221.SL.SR	SL.C2	0.15625	1.005	0.035	20100216.HN.PD	HN.C2	0.625	1.033	0.125
20091221.SL.SR	SL.C3	0.3125	1.017	0.046	20100216.HN.PD	HN.C3	1.25	0.967	0.092
20091221.SL.SR	SL.C4	0.625	1.019	0.031	20100216.HN.PD	HN.C4	2.5	0.773	0.073
20091221.SL.SR	SL.C5	1.25	0.904	0.044	20100216.HN.PD	HN.C5	5	0.511	0.038
20091221.SL.SR	SL.C6	2.5	0.966	0.035	20100216.HN.PD	HN.C6	10	0.256	0.027
20091221.SL.SR	SL.C7	5	0.903	0.049	20100216.HN.PD	HN.C7	20	0.013	0.003
20091221.SL.SR	SL.SR.C1	SL.SR.C1	1.144	0.076	20100216.HN.PD	HN.PD.C1	HN.PD.C1	1.021	0.047
20091221.SL.SR	SL.SR.C2	SL.SR.C2	1.166	0.075	20100216.HN.PD	HN.PD.C2	HN.PD.C2	0.96	0.035
20091221.SL.SR	SL.SR.C3	SL.SR.C3	1.264	0.095	20100216.HN.PD	HN.PD.C3	HN.PD.C3	0.778	0.078
20091221.SL.SR	SL.SR.C4	SL.SR.C4	0.994	0.102	20100216.HN.PD	HN.PD.C4	HN.PD.C4	0.58	0.015
20091221.SL.SR	SL.SR.C5	SL.SR.C5	1.074	0.111	20100216.HN.PD	HN.PD.C5	HN.PD.C5	0.421	0.015
20091221.SL.SR	SL.SR.C6	SL.SR.C6	1.084	0.06	20100216.HN.PD	HN.PD.C6	HN.PD.C6	0.195	0.017

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091221.SL.SR	SL.SR.C7	SL.SR.C7	0.916	0.099	20100216.HN.PD	HN.PD.C7	HN.PD.C7	0.027	0.005
20091221.SL.SR	SR.C1	0.078125	0.946	0.098	20100216.HN.PD	PD.C1	0.15625	1.247	0.119
20091221.SL.SR	SR.C2	0.15625	0.998	0.116	20100216.HN.PD	PD.C2	0.3125	1.029	0.057
20091221.SL.SR	SR.C3	0.3125	1.069	0.123	20100216.HN.PD	PD.C3	0.625	1.023	0.061
20091221.SL.SR	SR.C4	0.625	1.089	0.115	20100216.HN.PD	PD.C4	1.25	0.884	0.064
20091221.SL.SR	SR.C5	1.25	1.058	0.12	20100216.HN.PD	PD.C5	2.5	0.681	0.08
20091221.SL.SR	SR.C6	2.5	1.093	0.121	20100216.HN.PD	PD.C6	5	0.425	0.011
20091221.SL.SR	SR.C7	5	1.044	0.156	20100216.HN.PD	PD.C7	10	0.284	0.013
20091229.PD.RT	PD.C1	0.15625	1.034	0.015	20100216.PD.RY	PD.C1	0.15625	1.247	0.119
20091229.PD.RT	PD.C2	0.3125	1.014	0.032	20100216.PD.RY	PD.C2	0.3125	1.029	0.057
20091229.PD.RT	PD.C3	0.625	0.997	0.041	20100216.PD.RY	PD.C3	0.625	1.023	0.061
20091229.PD.RT	PD.C4	1.25	0.923	0.098	20100216.PD.RY	PD.C4	1.25	0.884	0.064
20091229.PD.RT	PD.C5	2.5	0.733	0.059	20100216.PD.RY	PD.C5	2.5	0.681	0.08
20091229.PD.RT	PD.C6	5	0.551	0.085	20100216.PD.RY	PD.C6	5	0.425	0.011
20091229.PD.RT	PD.C7	10	0.366	0.034	20100216.PD.RY	PD.C7	10	0.284	0.013
20091229.PD.RT	PD.RT.C1	PD.RT.C1	0.954	0.07	20100216.PD.RY	PD.RY.C1	PD.RY.C1	0.973	0.027
20091229.PD.RT	PD.RT.C2	PD.RT.C2	0.983	0.078	20100216.PD.RY	PD.RY.C2	PD.RY.C2	0.938	0.046
20091229.PD.RT	PD.RT.C3	PD.RT.C3	0.899	0.085	20100216.PD.RY	PD.RY.C3	PD.RY.C3	0.853	0.078
20091229.PD.RT	PD.RT.C4	PD.RT.C4	0.743	0.088	20100216.PD.RY	PD.RY.C4	PD.RY.C4	0.73	0.049
20091229.PD.RT	PD.RT.C5	PD.RT.C5	0.587	0.036	20100216.PD.RY	PD.RY.C5	PD.RY.C5	0.565	0.022
20091229.PD.RT	PD.RT.C6	PD.RT.C6	0.227	0.043	20100216.PD.RY	PD.RY.C6	PD.RY.C6	0.296	0.019
20091229.PD.RT	PD.RT.C7	PD.RT.C7	0.147	0.011	20100216.PD.RY	PD.RY.C7	PD.RY.C7	0.075	0.005
20091229.PD.RT	RT.C1	0.078125	1.083	0.032	20100216.PD.RY	RY.C1	0.03125	1.235	0.029
20091229.PD.RT	RT.C2	0.15625	1.05	0.033	20100216.PD.RY	RY.C2	0.0625	1.294	0.032
20091229.PD.RT	RT.C3	0.3125	0.979	0.079	20100216.PD.RY	RY.C3	0.125	1.351	0.055
20091229.PD.RT	RT.C4	0.625	1.012	0.095	20100216.PD.RY	RY.C4	0.25	1.302	0.054
20091229.PD.RT	RT.C5	1.25	0.756	0.054	20100216.PD.RY	RY.C5	0.5	1.037	0.11
20091229.PD.RT	RT.C6	2.5	0.327	0.049	20100216.PD.RY	RY.C6	1	0.446	0.094
20091229.PD.RT	RT.C7	5	0.164	0.014	20100216.PD.RY	RY.C7	2	0.059	0.002
20091229.PD.ST	PD.C1	0.15625	1.034	0.015	20100216.RY.SL	RY.C1	0.03125	1.235	0.029
20091229.PD.ST	PD.C2	0.3125	1.014	0.032	20100216.RY.SL	RY.C2	0.0625	1.294	0.032
20091229.PD.ST	PD.C3	0.625	0.997	0.041	20100216.RY.SL	RY.C3	0.125	1.351	0.055
20091229.PD.ST	PD.C4	1.25	0.923	0.098	20100216.RY.SL	RY.C4	0.25	1.302	0.054
20091229.PD.ST	PD.C5	2.5	0.733	0.059	20100216.RY.SL	RY.C5	0.5	1.037	0.11
20091229.PD.ST	PD.C6	5	0.551	0.085	20100216.RY.SL	RY.C6	1	0.446	0.094
20091229.PD.ST	PD.C7	10	0.366	0.034	20100216.RY.SL	RY.C7	2	0.059	0.002
20091229.PD.ST	PD.ST.C1	PD.ST.C1	1.011	0.056	20100216.RY.SL	RY.SL.C1	RY.SL.C1	1.021	0.043
20091229.PD.ST	PD.ST.C2	PD.ST.C2	1.008	0.07	20100216.RY.SL	RY.SL.C2	RY.SL.C2	1.087	0.053
20091229.PD.ST	PD.ST.C3	PD.ST.C3	0.781	0.065	20100216.RY.SL	RY.SL.C3	RY.SL.C3	1.13	0.044
20091229.PD.ST	PD.ST.C4	PD.ST.C4	0.511	0.085	20100216.RY.SL	RY.SL.C4	RY.SL.C4	1.09	0.084
20091229.PD.ST	PD.ST.C5	PD.ST.C5	0.228	0.033	20100216.RY.SL	RY.SL.C5	RY.SL.C5	1.042	0.047
20091229.PD.ST	PD.ST.C6	PD.ST.C6	0.001	0.001	20100216.RY.SL	RY.SL.C6	RY.SL.C6	0.478	0.026
20091229.PD.ST	PD.ST.C7	PD.ST.C7	-0.003	0.001	20100216.RY.SL	RY.SL.C7	RY.SL.C7	0.056	0.001
20091229.PD.ST	ST.C1	0.078125	1.014	0.068	20100216.RY.SL	SL.C1	0.078125	1.117	0.041
20091229.PD.ST	ST.C2	0.15625	0.998	0.058	20100216.RY.SL	SL.C2	0.15625	1.076	0.044
20091229.PD.ST	ST.C3	0.3125	0.873	0.026	20100216.RY.SL	SL.C3	0.3125	1.052	0.055
20091229.PD.ST	ST.C4	0.625	0.595	0.05	20100216.RY.SL	SL.C4	0.625	0.953	0.059
20091229.PD.ST	ST.C5	1.25	0.277	0.036	20100216.RY.SL	SL.C5	1.25	0.992	0.064
20091229.PD.ST	ST.C6	2.5	0.011	0.012	20100216.RY.SL	SL.C6	2.5	0.887	0.078
20091229.PD.ST	ST.C7	5	-0.001	0.002	20100216.RY.SL	SL.C7	5	0.851	0.085
20091229.PD.SU	PD.C1	0.15625	1.034	0.015	20100216.RY.SR	RY.C1	0.03125	1.235	0.029
20091229.PD.SU	PD.C2	0.3125	1.014	0.032	20100216.RY.SR	RY.C2	0.0625	1.294	0.032
20091229.PD.SU	PD.C3	0.625	0.997	0.041	20100216.RY.SR	RY.C3	0.125	1.351	0.055
20091229.PD.SU	PD.C4	1.25	0.923	0.098	20100216.RY.SR	RY.C4	0.25	1.302	0.054
20091229.PD.SU	PD.C5	2.5	0.733	0.059	20100216.RY.SR	RY.C5	0.5	1.037	0.11
20091229.PD.SU	PD.C6	5	0.551	0.085	20100216.RY.SR	RY.C6	1	0.446	0.094
20091229.PD.SU	PD.C7	10	0.366	0.034	20100216.RY.SR	RY.C7	2	0.059	0.002
20091229.PD.SU	PD.SU.C1	PD.SU.C1	1.049	0.047	20100216.RY.SR	RY.SR.C1	RY.SR.C1	1.08	0.046
20091229.PD.SU	PD.SU.C2	PD.SU.C2	1.039	0.056	20100216.RY.SR	RY.SR.C2	RY.SR.C2	1.144	0.059
20091229.PD.SU	PD.SU.C3	PD.SU.C3	0.937	0.059	20100216.RY.SR	RY.SR.C3	RY.SR.C3	1.149	0.032
20091229.PD.SU	PD.SU.C4	PD.SU.C4	0.8	0.033	20100216.RY.SR	RY.SR.C4	RY.SR.C4	1.277	0.058
20091229.PD.SU	PD.SU.C5	PD.SU.C5	0.551	0.043	20100216.RY.SR	RY.SR.C5	RY.SR.C5	1.277	0.057
20091229.PD.SU	PD.SU.C6	PD.SU.C6	0.441	0.052	20100216.RY.SR	RY.SR.C6	RY.SR.C6	0.758	0.032
20091229.PD.SU	PD.SU.C7	PD.SU.C7	0.178	0.018	20100216.RY.SR	RY.SR.C7	RY.SR.C7	0.05	0.003
20091229.PD.SU	SU.C1	0.3125	1.095	0.065	20100216.RY.SR	SR.C1	0.078125	1.15	0.052
20091229.PD.SU	SU.C2	0.625	1.083	0.079	20100216.RY.SR	SR.C2	0.15625	1.164	0.051
20091229.PD.SU	SU.C3	1.25	1.092	0.089	20100216.RY.SR	SR.C3	0.3125	1.137	0.056
20091229.PD.SU	SU.C4	2.5	0.926	0.081	20100216.RY.SR	SR.C4	0.625	1.172	0.083
20091229.PD.SU	SU.C5	5	0.721	0.096	20100216.RY.SR	SR.C5	1.25	1.108	0.066

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20091229.PD.SU	SU.C6	10	0.568	0.066	20100216.RY.SR	SR.C6	2.5	1.166	0.057
20091229.PD.SU	SU.C7	20	0.482	0.085	20100216.RY.SR	SR.C7	5	1.019	0.059
20091229.RT.ST	RT.C1	0.078125	1.083	0.032	20100216.RY.SU	RY.C1	0.03125	1.235	0.029
20091229.RT.ST	RT.C2	0.15625	1.05	0.033	20100216.RY.SU	RY.C2	0.0625	1.294	0.032
20091229.RT.ST	RT.C3	0.3125	0.979	0.079	20100216.RY.SU	RY.C3	0.125	1.351	0.055
20091229.RT.ST	RT.C4	0.625	1.012	0.095	20100216.RY.SU	RY.C4	0.25	1.302	0.054
20091229.RT.ST	RT.C5	1.25	0.756	0.054	20100216.RY.SU	RY.C5	0.5	1.037	0.11
20091229.RT.ST	RT.C6	2.5	0.327	0.049	20100216.RY.SU	RY.C6	1	0.446	0.094
20091229.RT.ST	RT.C7	5	0.164	0.014	20100216.RY.SU	RY.C7	2	0.059	0.002
20091229.RT.ST	RT.ST.C1	RT.ST.C1	1.087	0.076	20100216.RY.SU	RY.SU.C1	RY.SU.C1	0.823	0.036
20091229.RT.ST	RT.ST.C2	RT.ST.C2	1.119	0.102	20100216.RY.SU	RY.SU.C2	RY.SU.C2	0.817	0.045
20091229.RT.ST	RT.ST.C3	RT.ST.C3	0.935	0.104	20100216.RY.SU	RY.SU.C3	RY.SU.C3	0.827	0.039
20091229.RT.ST	RT.ST.C4	RT.ST.C4	0.543	0.076	20100216.RY.SU	RY.SU.C4	RY.SU.C4	0.853	0.033
20091229.RT.ST	RT.ST.C5	RT.ST.C5	0.114	0.027	20100216.RY.SU	RY.SU.C5	RY.SU.C5	0.708	0.096
20091229.RT.ST	RT.ST.C6	RT.ST.C6	0.005	0.001	20100216.RY.SU	RY.SU.C6	RY.SU.C6	0.057	0.071
20091229.RT.ST	RT.ST.C7	RT.ST.C7	-0.004	0.001	20100216.RY.SU	RY.SU.C7	RY.SU.C7	0.044	0.004
20091229.RT.ST	ST.C1	0.078125	1.014	0.068	20100216.RY.SU	SU.C1	0.3125	1.171	0.114
20091229.RT.ST	ST.C2	0.15625	0.998	0.058	20100216.RY.SU	SU.C2	0.625	1.137	0.118
20091229.RT.ST	ST.C3	0.3125	0.873	0.026	20100216.RY.SU	SU.C3	1.25	1.058	0.041
20091229.RT.ST	ST.C4	0.625	0.595	0.05	20100216.RY.SU	SU.C4	2.5	0.818	0.05
20091229.RT.ST	ST.C5	1.25	0.277	0.036	20100216.RY.SU	SU.C5	5	0.605	0.059
20091229.RT.ST	ST.C6	2.5	0.011	0.012	20100216.RY.SU	SU.C6	10	0.575	0.026
20091229.RT.ST	ST.C7	5	-0.001	0.002	20100216.RY.SU	SU.C7	20	0.316	0.025
20091229.RT.SU	RT.C1	0.078125	1.083	0.032	20100216.SR.SU	SR.C1	0.078125	1.15	0.052
20091229.RT.SU	RT.C2	0.15625	1.05	0.033	20100216.SR.SU	SR.C2	0.15625	1.164	0.051
20091229.RT.SU	RT.C3	0.3125	0.979	0.079	20100216.SR.SU	SR.C3	0.3125	1.137	0.056
20091229.RT.SU	RT.C4	0.625	1.012	0.095	20100216.SR.SU	SR.C4	0.625	1.172	0.083
20091229.RT.SU	RT.C5	1.25	0.756	0.054	20100216.SR.SU	SR.C5	1.25	1.108	0.066
20091229.RT.SU	RT.C6	2.5	0.327	0.049	20100216.SR.SU	SR.C6	2.5	1.166	0.057
20091229.RT.SU	RT.C7	5	0.164	0.014	20100216.SR.SU	SR.C7	5	1.019	0.059
20091229.RT.SU	RT.SU.C1	RT.SU.C1	1.198	0.1	20100216.SR.SU	SR.SU.C1	SR.SU.C1	1.033	0.027
20091229.RT.SU	RT.SU.C2	RT.SU.C2	1.091	0.091	20100216.SR.SU	SR.SU.C2	SR.SU.C2	1.093	0.061
20091229.RT.SU	RT.SU.C3	RT.SU.C3	1.103	0.111	20100216.SR.SU	SR.SU.C3	SR.SU.C3	1.084	0.035
20091229.RT.SU	RT.SU.C4	RT.SU.C4	0.94	0.128	20100216.SR.SU	SR.SU.C4	SR.SU.C4	0.979	0.022
20091229.RT.SU	RT.SU.C5	RT.SU.C5	0.315	0.069	20100216.SR.SU	SR.SU.C5	SR.SU.C5	0.689	0.036
20091229.RT.SU	RT.SU.C6	RT.SU.C6	0.155	0.029	20100216.SR.SU	SR.SU.C6	SR.SU.C6	0.512	0.018
20091229.RT.SU	RT.SU.C7	RT.SU.C7	0.068	0.015	20100216.SR.SU	SR.SU.C7	SR.SU.C7	0.328	0.019
20091229.RT.SU	SU.C1	0.3125	1.095	0.065	20100216.SR.SU	SU.C1	0.3125	1.171	0.114
20091229.RT.SU	SU.C2	0.625	1.083	0.079	20100216.SR.SU	SU.C2	0.625	1.137	0.118
20091229.RT.SU	SU.C3	1.25	1.092	0.089	20100216.SR.SU	SU.C3	1.25	1.058	0.041
20091229.RT.SU	SU.C4	2.5	0.926	0.081	20100216.SR.SU	SU.C4	2.5	0.818	0.05
20091229.RT.SU	SU.C5	5	0.721	0.096	20100216.SR.SU	SU.C5	5	0.605	0.059
20091229.RT.SU	SU.C6	10	0.568	0.066	20100216.SR.SU	SU.C6	10	0.575	0.026
20091229.RT.SU	SU.C7	20	0.482	0.085	20100216.SR.SU	SU.C7	20	0.316	0.025
20091229.ST.SU	ST.C1	0.078125	1.014	0.068	20100223.AK.ST	AK.C1	0.3125	0.854	0.096
20091229.ST.SU	ST.C2	0.15625	0.998	0.058	20100223.AK.ST	AK.C2	0.625	0.859	0.038
20091229.ST.SU	ST.C3	0.3125	0.873	0.026	20100223.AK.ST	AK.C3	1.25	0.839	0.028
20091229.ST.SU	ST.C4	0.625	0.595	0.05	20100223.AK.ST	AK.C4	2.5	0.831	0.046
20091229.ST.SU	ST.C5	1.25	0.277	0.036	20100223.AK.ST	AK.C5	5	0.703	0.052
20091229.ST.SU	ST.C6	2.5	0.011	0.012	20100223.AK.ST	AK.C6	10	0.376	0.024
20091229.ST.SU	ST.C7	5	-0.001	0.002	20100223.AK.ST	AK.C7	20	0.217	0.015
20091229.ST.SU	ST.SU.C1	ST.SU.C1	0.972	0.07	20100223.AK.ST	AK.ST.C1	AK.ST.C1	1.032	0.055
20091229.ST.SU	ST.SU.C2	ST.SU.C2	1.052	0.05	20100223.AK.ST	AK.ST.C2	AK.ST.C2	0.931	0.061
20091229.ST.SU	ST.SU.C3	ST.SU.C3	0.867	0.054	20100223.AK.ST	AK.ST.C3	AK.ST.C3	0.64	0.07
20091229.ST.SU	ST.SU.C4	ST.SU.C4	0.637	0.047	20100223.AK.ST	AK.ST.C4	AK.ST.C4	0.393	0.03
20091229.ST.SU	ST.SU.C5	ST.SU.C5	0.152	0.018	20100223.AK.ST	AK.ST.C5	AK.ST.C5	0.029	0.007
20091229.ST.SU	ST.SU.C6	ST.SU.C6	0.014	0.001	20100223.AK.ST	AK.ST.C6	AK.ST.C6	0.006	0.002
20091229.ST.SU	ST.SU.C7	ST.SU.C7	0.01	0.001	20100223.AK.ST	AK.ST.C7	AK.ST.C7	-0.007	0.005
20091229.ST.SU	SU.C1	0.3125	1.095	0.065	20100223.AK.ST	ST.C1	0.078125	0.629	0.082
20091229.ST.SU	SU.C2	0.625	1.083	0.079	20100223.AK.ST	ST.C2	0.15625	0.752	0.062
20091229.ST.SU	SU.C3	1.25	1.092	0.089	20100223.AK.ST	ST.C3	0.3125	0.417	0.028
20091229.ST.SU	SU.C4	2.5	0.926	0.081	20100223.AK.ST	ST.C4	0.625	0.306	0.023
20091229.ST.SU	SU.C5	5	0.721	0.096	20100223.AK.ST	ST.C5	1.25	0.036	0.007
20091229.ST.SU	SU.C6	10	0.568	0.066	20100223.AK.ST	ST.C6	2.5	0.01	0.001
20091229.ST.SU	SU.C7	20	0.482	0.085	20100223.AK.ST	ST.C7	5	0.008	0.001
20100126.GF.SL	GF.C1	0.3125	1.068	0.043	20100223.ER.RY	ER.C1	0.078125	1.037	0.025
20100126.GF.SL	GF.C2	0.625	1.123	0.073	20100223.ER.RY	ER.C2	0.15625	1.1	0.05
20100126.GF.SL	GF.C3	1.25	1.108	0.043	20100223.ER.RY	ER.C3	0.3125	0.984	0.062
20100126.GF.SL	GF.C4	2.5	1.003	0.1	20100223.ER.RY	ER.C4	0.625	0.971	0.097

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20100126.GF.SL	GF.C5	5	0.926	0.062	20100223.ER.RY	ER.C5	1.25	0.952	0.105
20100126.GF.SL	GF.C6	10	0.759	0.09	20100223.ER.RY	ER.C6	2.5	0.845	0.106
20100126.GF.SL	GF.C7	20	0.391	0.089	20100223.ER.RY	ER.C7	5	0.922	0.056
20100126.GF.SL	GF.SL.C1	GF.SL.C1	1.005	0.04	20100223.ER.RY	ER.RY.C1	ER.RY.C1	1.177	0.139
20100126.GF.SL	GF.SL.C2	GF.SL.C2	1.008	0.046	20100223.ER.RY	ER.RY.C2	ER.RY.C2	1.046	0.114
20100126.GF.SL	GF.SL.C3	GF.SL.C3	0.949	0.04	20100223.ER.RY	ER.RY.C3	ER.RY.C3	1.266	0.037
20100126.GF.SL	GF.SL.C4	GF.SL.C4	0.946	0.07	20100223.ER.RY	ER.RY.C4	ER.RY.C4	1.29	0.019
20100126.GF.SL	GF.SL.C5	GF.SL.C5	0.881	0.035	20100223.ER.RY	ER.RY.C5	ER.RY.C5	1.282	0.036
20100126.GF.SL	GF.SL.C6	GF.SL.C6	0.677	0.012	20100223.ER.RY	ER.RY.C6	ER.RY.C6	0.765	0.037
20100126.GF.SL	GF.SL.C7	GF.SL.C7	0.341	0.034	20100223.ER.RY	ER.RY.C7	ER.RY.C7	0.067	0.008
20100126.GF.SL	SL.C1	0.078125	1.023	0.014	20100223.ER.RY	RY.C1	0.03125	1.021	0.105
20100126.GF.SL	SL.C2	0.15625	1.047	0.037	20100223.ER.RY	RY.C2	0.0625	1.051	0.067
20100126.GF.SL	SL.C3	0.3125	1.047	0.072	20100223.ER.RY	RY.C3	0.125	1.113	0.045
20100126.GF.SL	SL.C4	0.625	1.071	0.101	20100223.ER.RY	RY.C4	0.25	1.192	0.068
20100126.GF.SL	SL.C5	1.25	1.035	0.045	20100223.ER.RY	RY.C5	0.5	1.216	0.049
20100126.GF.SL	SL.C6	2.5	0.997	0.039	20100223.ER.RY	RY.C6	1	0.746	0.058
20100126.GF.SL	SL.C7	5	0.977	0.023	20100223.ER.RY	RY.C7	2	0.065	0.005
20100126.GF.SR	GF.C1	0.3125	1.068	0.043	20100223.ER.ST	ER.C1	0.078125	1.037	0.025
20100126.GF.SR	GF.C2	0.625	1.123	0.073	20100223.ER.ST	ER.C2	0.15625	1.1	0.05
20100126.GF.SR	GF.C3	1.25	1.108	0.043	20100223.ER.ST	ER.C3	0.3125	0.984	0.062
20100126.GF.SR	GF.C4	2.5	1.003	0.1	20100223.ER.ST	ER.C4	0.625	0.971	0.097
20100126.GF.SR	GF.C5	5	0.926	0.062	20100223.ER.ST	ER.C5	1.25	0.952	0.105
20100126.GF.SR	GF.C6	10	0.759	0.09	20100223.ER.ST	ER.C6	2.5	0.845	0.106
20100126.GF.SR	GF.C7	20	0.391	0.089	20100223.ER.ST	ER.C7	5	0.922	0.056
20100126.GF.SR	GF.SR.C1	GF.SR.C1	1.043	0.031	20100223.ER.ST	ER.ST.C1	ER.ST.C1	1.109	0.053
20100126.GF.SR	GF.SR.C2	GF.SR.C2	0.978	0.063	20100223.ER.ST	ER.ST.C2	ER.ST.C2	1.056	0.066
20100126.GF.SR	GF.SR.C3	GF.SR.C3	0.986	0.053	20100223.ER.ST	ER.ST.C3	ER.ST.C3	0.681	0.065
20100126.GF.SR	GF.SR.C4	GF.SR.C4	1.004	0.074	20100223.ER.ST	ER.ST.C4	ER.ST.C4	0.325	0.034
20100126.GF.SR	GF.SR.C5	GF.SR.C5	0.95	0.051	20100223.ER.ST	ER.ST.C5	ER.ST.C5	0.053	0.027
20100126.GF.SR	GF.SR.C6	GF.SR.C6	0.741	0.075	20100223.ER.ST	ER.ST.C6	ER.ST.C6	0.007	0.001
20100126.GF.SR	GF.SR.C7	GF.SR.C7	0.24	0.035	20100223.ER.ST	ER.ST.C7	ER.ST.C7	0.005	0.004
20100126.GF.SR	SR.C1	0.078125	1.039	0.031	20100223.ER.ST	ST.C1	0.078125	0.629	0.082
20100126.GF.SR	SR.C2	0.15625	1.027	0.038	20100223.ER.ST	ST.C2	0.15625	0.752	0.062
20100126.GF.SR	SR.C3	0.3125	1.003	0.069	20100223.ER.ST	ST.C3	0.3125	0.417	0.028
20100126.GF.SR	SR.C4	0.625	1.045	0.083	20100223.ER.ST	ST.C4	0.625	0.306	0.023
20100126.GF.SR	SR.C5	1.25	0.859	0.048	20100223.ER.ST	ST.C5	1.25	0.036	0.007
20100126.GF.SR	SR.C6	2.5	1.056	0.077	20100223.ER.ST	ST.C6	2.5	0.01	0.001
20100126.GF.SR	SR.C7	5	1.069	0.053	20100223.ER.ST	ST.C7	5	0.008	0.001
20100126.GF.ST	GF.C1	0.3125	1.068	0.043	20100223.GF.PD	GF.C1	0.3125	0.922	0.063
20100126.GF.ST	GF.C2	0.625	1.123	0.073	20100223.GF.PD	GF.C2	0.625	0.97	0.067
20100126.GF.ST	GF.C3	1.25	1.108	0.043	20100223.GF.PD	GF.C3	1.25	0.964	0.106
20100126.GF.ST	GF.C4	2.5	1.003	0.1	20100223.GF.PD	GF.C4	2.5	0.969	0.044
20100126.GF.ST	GF.C5	5	0.926	0.062	20100223.GF.PD	GF.C5	5	0.846	0.063
20100126.GF.ST	GF.C6	10	0.759	0.09	20100223.GF.PD	GF.C6	10	0.525	0.063
20100126.GF.ST	GF.C7	20	0.391	0.089	20100223.GF.PD	GF.C7	20	0.221	0.03
20100126.GF.ST	GF.ST.C1	GF.ST.C1	1.048	0.033	20100223.GF.PD	GF.PD.C1	GF.PD.C1	0.787	0.081
20100126.GF.ST	GF.ST.C2	GF.ST.C2	1.001	0.041	20100223.GF.PD	GF.PD.C2	GF.PD.C2	0.756	0.078
20100126.GF.ST	GF.ST.C3	GF.ST.C3	0.875	0.085	20100223.GF.PD	GF.PD.C3	GF.PD.C3	0.736	0.08
20100126.GF.ST	GF.ST.C4	GF.ST.C4	0.44	0.04	20100223.GF.PD	GF.PD.C4	GF.PD.C4	0.619	0.058
20100126.GF.ST	GF.ST.C5	GF.ST.C5	0.236	0.031	20100223.GF.PD	GF.PD.C5	GF.PD.C5	0.433	0.031
20100126.GF.ST	GF.ST.C6	GF.ST.C6	0.01	0.001	20100223.GF.PD	GF.PD.C6	GF.PD.C6	0.209	0.022
20100126.GF.ST	GF.ST.C7	GF.ST.C7	0	0	20100223.GF.PD	GF.PD.C7	GF.PD.C7	0.097	0.009
20100126.GF.ST	ST.C1	0.078125	1.215	0.079	20100223.GF.PD	PD.C1	0.15625	1.02	0.039
20100126.GF.ST	ST.C2	0.15625	1.221	0.103	20100223.GF.PD	PD.C2	0.3125	0.989	0.033
20100126.GF.ST	ST.C3	0.3125	0.97	0.125	20100223.GF.PD	PD.C3	0.625	0.974	0.085
20100126.GF.ST	ST.C4	0.625	0.514	0.139	20100223.GF.PD	PD.C4	1.25	0.771	0.065
20100126.GF.ST	ST.C5	1.25	0.429	0.132	20100223.GF.PD	PD.C5	2.5	0.587	0.028
20100126.GF.ST	ST.C6	2.5	0.017	0.007	20100223.GF.PD	PD.C6	5	0.371	0.024
20100126.GF.ST	ST.C7	5	0.001	0.001	20100223.GF.PD	PD.C7	10	0.225	0.023
20100126.SL.SR	SL.C1	0.078125	1.023	0.014	20100223.GF.RY	GF.C1	0.3125	0.922	0.063
20100126.SL.SR	SL.C2	0.15625	1.047	0.037	20100223.GF.RY	GF.C2	0.625	0.97	0.067
20100126.SL.SR	SL.C3	0.3125	1.047	0.072	20100223.GF.RY	GF.C3	1.25	0.964	0.106
20100126.SL.SR	SL.C4	0.625	1.071	0.101	20100223.GF.RY	GF.C4	2.5	0.969	0.044
20100126.SL.SR	SL.C5	1.25	1.035	0.045	20100223.GF.RY	GF.C5	5	0.846	0.063
20100126.SL.SR	SL.C6	2.5	0.997	0.039	20100223.GF.RY	GF.C6	10	0.525	0.063
20100126.SL.SR	SL.C7	5	0.977	0.023	20100223.GF.RY	GF.C7	20	0.221	0.03
20100126.SL.SR	SL.SR.C1	SL.SR.C1	1.037	0.036	20100223.GF.RY	GF.RY.C1	GF.RY.C1	0.964	0.04
20100126.SL.SR	SL.SR.C2	SL.SR.C2	1.031	0.052	20100223.GF.RY	GF.RY.C2	GF.RY.C2	0.934	0.03
20100126.SL.SR	SL.SR.C3	SL.SR.C3	1.054	0.061	20100223.GF.RY	GF.RY.C3	GF.RY.C3	0.92	0.046

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20100126.SL.SR	SL.SR.C4	SL.SR.C4	1.046	0.031	20100223.GF.RY	GF.RY.C4	GF.RY.C4	0.958	0.039
20100126.SL.SR	SL.SR.C5	SL.SR.C5	1.043	0.028	20100223.GF.RY	GF.RY.C5	GF.RY.C5	0.633	0.036
20100126.SL.SR	SL.SR.C6	SL.SR.C6	1.017	0.048	20100223.GF.RY	GF.RY.C6	GF.RY.C6	0.236	0.046
20100126.SL.SR	SL.SR.C7	SL.SR.C7	0.992	0.033	20100223.GF.RY	GF.RY.C7	GF.RY.C7	0.033	0.004
20100126.SL.SR	SR.C1	0.078125	1.039	0.031	20100223.GF.RY	RY.C1	0.03125	1.021	0.105
20100126.SL.SR	SR.C2	0.15625	1.027	0.038	20100223.GF.RY	RY.C2	0.0625	1.051	0.067
20100126.SL.SR	SR.C3	0.3125	1.003	0.069	20100223.GF.RY	RY.C3	0.125	1.113	0.045
20100126.SL.SR	SR.C4	0.625	1.045	0.083	20100223.GF.RY	RY.C4	0.25	1.192	0.068
20100126.SL.SR	SR.C5	1.25	0.859	0.048	20100223.GF.RY	RY.C5	0.5	1.216	0.049
20100126.SL.SR	SR.C6	2.5	1.056	0.077	20100223.GF.RY	RY.C6	1	0.746	0.058
20100126.SL.SR	SR.C7	5	1.069	0.053	20100223.GF.RY	RY.C7	2	0.065	0.005
20100126.SL.ST	SL.C1	0.078125	1.023	0.014	20100223.GF.SU	GF.C1	0.3125	0.922	0.063
20100126.SL.ST	SL.C2	0.15625	1.047	0.037	20100223.GF.SU	GF.C2	0.625	0.97	0.067
20100126.SL.ST	SL.C3	0.3125	1.047	0.072	20100223.GF.SU	GF.C3	1.25	0.964	0.106
20100126.SL.ST	SL.C4	0.625	1.071	0.101	20100223.GF.SU	GF.C4	2.5	0.969	0.044
20100126.SL.ST	SL.C5	1.25	1.035	0.045	20100223.GF.SU	GF.C5	5	0.846	0.063
20100126.SL.ST	SL.C6	2.5	0.997	0.039	20100223.GF.SU	GF.C6	10	0.525	0.063
20100126.SL.ST	SL.C7	5	0.977	0.023	20100223.GF.SU	GF.C7	20	0.221	0.03
20100126.SL.ST	SL.ST.C1	SL.ST.C1	1.099	0.017	20100223.GF.SU	GF.SU.C1	GF.SU.C1	1.085	0.067
20100126.SL.ST	SL.ST.C2	SL.ST.C2	1.104	0.028	20100223.GF.SU	GF.SU.C2	GF.SU.C2	1.024	0.062
20100126.SL.ST	SL.ST.C3	SL.ST.C3	0.954	0.063	20100223.GF.SU	GF.SU.C3	GF.SU.C3	0.908	0.033
20100126.SL.ST	SL.ST.C4	SL.ST.C4	0.524	0.035	20100223.GF.SU	GF.SU.C4	GF.SU.C4	0.579	0.021
20100126.SL.ST	SL.ST.C5	SL.ST.C5	0.351	0.054	20100223.GF.SU	GF.SU.C5	GF.SU.C5	0.356	0.028
20100126.SL.ST	SL.ST.C6	SL.ST.C6	0.018	0.006	20100223.GF.SU	GF.SU.C6	GF.SU.C6	0.207	0.017
20100126.SL.ST	SL.ST.C7	SL.ST.C7	-0.001	0.001	20100223.GF.SU	GF.SU.C7	GF.SU.C7	0.095	0.008
20100126.SL.ST	ST.C1	0.078125	1.215	0.079	20100223.GF.SU	SU.C1	0.3125	1.026	0.036
20100126.SL.ST	ST.C2	0.15625	1.221	0.103	20100223.GF.SU	SU.C2	0.625	1.059	0.039
20100126.SL.ST	ST.C3	0.3125	0.97	0.125	20100223.GF.SU	SU.C3	1.25	1.012	0.077
20100126.SL.ST	ST.C4	0.625	0.514	0.139	20100223.GF.SU	SU.C4	2.5	0.781	0.048
20100126.SL.ST	ST.C5	1.25	0.429	0.132	20100223.GF.SU	SU.C5	5	0.549	0.033
20100126.SL.ST	ST.C6	2.5	0.017	0.007	20100223.GF.SU	SU.C6	10	0.468	0.029
20100126.SL.ST	ST.C7	5	0.001	0.001	20100223.GF.SU	SU.C7	20	0.334	0.02
20100126.SR.ST	SR.C1	0.078125	1.039	0.031	20100223.HN.RY	HN.C1	0.3125	1.106	0.026
20100126.SR.ST	SR.C2	0.15625	1.027	0.038	20100223.HN.RY	HN.C2	0.625	1.088	0.053
20100126.SR.ST	SR.C3	0.3125	1.003	0.069	20100223.HN.RY	HN.C3	1.25	1.016	0.099
20100126.SR.ST	SR.C4	0.625	1.045	0.083	20100223.HN.RY	HN.C4	2.5	0.78	0.086
20100126.SR.ST	SR.C5	1.25	0.859	0.048	20100223.HN.RY	HN.C5	5	0.582	0.026
20100126.SR.ST	SR.C6	2.5	1.056	0.077	20100223.HN.RY	HN.C6	10	0.214	0.034
20100126.SR.ST	SR.C7	5	1.069	0.053	20100223.HN.RY	HN.C7	20	0.018	0.003
20100126.SR.ST	SR.ST.C1	SR.ST.C1	1.029	0.041	20100223.HN.RY	HN.RY.C1	HN.RY.C1	1.152	0.062
20100126.SR.ST	SR.ST.C2	SR.ST.C2	1.012	0.041	20100223.HN.RY	HN.RY.C2	HN.RY.C2	1.098	0.088
20100126.SR.ST	SR.ST.C3	SR.ST.C3	0.911	0.042	20100223.HN.RY	HN.RY.C3	HN.RY.C3	1.055	0.098
20100126.SR.ST	SR.ST.C4	SR.ST.C4	0.52	0.066	20100223.HN.RY	HN.RY.C4	HN.RY.C4	0.749	0.031
20100126.SR.ST	SR.ST.C5	SR.ST.C5	0.343	0.043	20100223.HN.RY	HN.RY.C5	HN.RY.C5	0.421	0.025
20100126.SR.ST	SR.ST.C6	SR.ST.C6	0.024	0.006	20100223.HN.RY	HN.RY.C6	HN.RY.C6	0.104	0.018
20100126.SR.ST	SR.ST.C7	SR.ST.C7	0	0.001	20100223.HN.RY	HN.RY.C7	HN.RY.C7	0.052	0.003
20100126.SR.ST	ST.C1	0.078125	1.215	0.079	20100223.HN.RY	RY.C1	0.03125	1.021	0.105
20100126.SR.ST	ST.C2	0.15625	1.221	0.103	20100223.HN.RY	RY.C2	0.0625	1.051	0.067
20100126.SR.ST	ST.C3	0.3125	0.97	0.125	20100223.HN.RY	RY.C3	0.125	1.113	0.045
20100126.SR.ST	ST.C4	0.625	0.514	0.139	20100223.HN.RY	RY.C4	0.25	1.192	0.068
20100126.SR.ST	ST.C5	1.25	0.429	0.132	20100223.HN.RY	RY.C5	0.5	1.216	0.049
20100126.SR.ST	ST.C6	2.5	0.017	0.007	20100223.HN.RY	RY.C6	1	0.746	0.058
20100126.SR.ST	ST.C7	5	0.001	0.001	20100223.HN.RY	RY.C7	2	0.065	0.005
20100129.ER.PD	ER.C1	0.078125	0.908	0.078	20100223.PI.RY	PI.C1	0.0625	0.967	0.061
20100129.ER.PD	ER.C2	0.15625	0.816	0.039	20100223.PI.RY	PI.C2	0.125	0.898	0.02
20100129.ER.PD	ER.C3	0.3125	0.859	0.056	20100223.PI.RY	PI.C3	0.25	0.811	0.057
20100129.ER.PD	ER.C4	0.625	0.768	0.06	20100223.PI.RY	PI.C4	0.5	0.652	0.07
20100129.ER.PD	ER.C5	1.25	0.771	0.065	20100223.PI.RY	PI.C5	1	0.459	0.039
20100129.ER.PD	ER.C6	2.5	0.766	0.115	20100223.PI.RY	PI.C6	2	0.311	0.03
20100129.ER.PD	ER.C7	5	0.768	0.093	20100223.PI.RY	PI.C7	4	0.235	0.022
20100129.ER.PD	ER.PD.C1	ER.PD.C1	0.934	0.067	20100223.PI.RY	PI.RY.C1	PI.RY.C1	0.976	0.031
20100129.ER.PD	ER.PD.C2	ER.PD.C2	0.956	0.11	20100223.PI.RY	PI.RY.C2	PI.RY.C2	0.963	0.031
20100129.ER.PD	ER.PD.C3	ER.PD.C3	0.793	0.09	20100223.PI.RY	PI.RY.C3	PI.RY.C3	0.75	0.064
20100129.ER.PD	ER.PD.C4	ER.PD.C4	0.743	0.07	20100223.PI.RY	PI.RY.C4	PI.RY.C4	0.567	0.029
20100129.ER.PD	ER.PD.C5	ER.PD.C5	0.621	0.053	20100223.PI.RY	PI.RY.C5	PI.RY.C5	0.366	0.024
20100129.ER.PD	ER.PD.C6	ER.PD.C6	0.425	0.103	20100223.PI.RY	PI.RY.C6	PI.RY.C6	0.228	0.01
20100129.ER.PD	ER.PD.C7	ER.PD.C7	0.344	0.015	20100223.PI.RY	PI.RY.C7	PI.RY.C7	0.124	0.022
20100129.ER.PD	PD.C1	0.15625	0.853	0.069	20100223.PI.RY	RY.C1	0.03125	1.021	0.105
20100129.ER.PD	PD.C2	0.3125	0.875	0.05	20100223.PI.RY	RY.C2	0.0625	1.051	0.067

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20100129.ER.PD	PD.C3	0.625	0.709	0.081	20100223.PI.RY	RY.C3	0.125	1.113	0.045
20100129.ER.PD	PD.C4	1.25	0.625	0.046	20100223.PI.RY	RY.C4	0.25	1.192	0.068
20100129.ER.PD	PD.C5	2.5	0.539	0.092	20100223.PI.RY	RY.C5	0.5	1.216	0.049
20100129.ER.PD	PD.C6	5	0.403	0.081	20100223.PI.RY	RY.C6	1	0.746	0.058
20100129.ER.PD	PD.C7	10	0.232	0.022	20100223.PI.RY	RY.C7	2	0.065	0.005
20100129.ER.PI	ER.C1	0.078125	0.908	0.078	20100223.PI.ST	PI.C1	0.0625	0.967	0.061
20100129.ER.PI	ER.C2	0.15625	0.816	0.039	20100223.PI.ST	PI.C2	0.125	0.898	0.02
20100129.ER.PI	ER.C3	0.3125	0.859	0.056	20100223.PI.ST	PI.C3	0.25	0.811	0.057
20100129.ER.PI	ER.C4	0.625	0.768	0.06	20100223.PI.ST	PI.C4	0.5	0.652	0.07
20100129.ER.PI	ER.C5	1.25	0.771	0.065	20100223.PI.ST	PI.C5	1	0.459	0.039
20100129.ER.PI	ER.C6	2.5	0.766	0.115	20100223.PI.ST	PI.C6	2	0.311	0.03
20100129.ER.PI	ER.C7	5	0.768	0.093	20100223.PI.ST	PI.C7	4	0.235	0.022
20100129.ER.PI	ER.PI.C1	ER.PI.C1	0.861	0.043	20100223.PI.ST	PI.ST.C1	PI.ST.C1	1.008	0.062
20100129.ER.PI	ER.PI.C2	ER.PI.C2	0.808	0.041	20100223.PI.ST	PI.ST.C2	PI.ST.C2	0.754	0.055
20100129.ER.PI	ER.PI.C3	ER.PI.C3	0.705	0.079	20100223.PI.ST	PI.ST.C3	PI.ST.C3	0.5	0.047
20100129.ER.PI	ER.PI.C4	ER.PI.C4	0.56	0.065	20100223.PI.ST	PI.ST.C4	PI.ST.C4	0.194	0.012
20100129.ER.PI	ER.PI.C5	ER.PI.C5	0.433	0.037	20100223.PI.ST	PI.ST.C5	PI.ST.C5	0.049	0.013
20100129.ER.PI	ER.PI.C6	ER.PI.C6	0.311	0.019	20100223.PI.ST	PI.ST.C6	PI.ST.C6	0.008	0.002
20100129.ER.PI	ER.PI.C7	ER.PI.C7	0.231	0.008	20100223.PI.ST	PI.ST.C7	PI.ST.C7	0.005	0.001
20100129.ER.PI	PI.C1	0.0625	0.928	0.037	20100223.PI.ST	ST.C1	0.078125	0.629	0.082
20100129.ER.PI	PI.C2	0.125	0.753	0.045	20100223.PI.ST	ST.C2	0.15625	0.752	0.062
20100129.ER.PI	PI.C3	0.25	0.687	0.086	20100223.PI.ST	ST.C3	0.3125	0.417	0.028
20100129.ER.PI	PI.C4	0.5	0.544	0.04	20100223.PI.ST	ST.C4	0.625	0.306	0.023
20100129.ER.PI	PI.C5	1	0.391	0.045	20100223.PI.ST	ST.C5	1.25	0.036	0.007
20100129.ER.PI	PI.C6	2	0.283	0.042	20100223.PI.ST	ST.C6	2.5	0.01	0.001
20100129.ER.PI	PI.C7	4	0.207	0.009	20100223.PI.ST	ST.C7	5	0.008	0.001
20100129.PD.PI	PD.C1	0.15625	0.853	0.069	20100226.AG.RT	AG.C1	0.078125	0.985	0.113
20100129.PD.PI	PD.C2	0.3125	0.875	0.05	20100226.AG.RT	AG.C2	0.15625	0.999	0.073
20100129.PD.PI	PD.C3	0.625	0.709	0.081	20100226.AG.RT	AG.C3	0.3125	1.018	0.065
20100129.PD.PI	PD.C4	1.25	0.625	0.046	20100226.AG.RT	AG.C4	0.625	1.112	0.08
20100129.PD.PI	PD.C5	2.5	0.539	0.092	20100226.AG.RT	AG.C5	1.25	1.041	0.048
20100129.PD.PI	PD.C6	5	0.403	0.081	20100226.AG.RT	AG.C6	2.5	1.059	0.09
20100129.PD.PI	PD.C7	10	0.232	0.022	20100226.AG.RT	AG.C7	5	0.926	0.078
20100129.PD.PI	PD.PI.C1	PD.PI.C1	0.818	0.05	20100226.AG.RT	AG.RT.C1	AG.RT.C1	1.016	0.125
20100129.PD.PI	PD.PI.C2	PD.PI.C2	0.764	0.062	20100226.AG.RT	AG.RT.C2	AG.RT.C2	1.028	0.093
20100129.PD.PI	PD.PI.C3	PD.PI.C3	0.611	0.086	20100226.AG.RT	AG.RT.C3	AG.RT.C3	0.998	0.139
20100129.PD.PI	PD.PI.C4	PD.PI.C4	0.49	0.031	20100226.AG.RT	AG.RT.C4	AG.RT.C4	0.936	0.083
20100129.PD.PI	PD.PI.C5	PD.PI.C5	0.346	0.035	20100226.AG.RT	AG.RT.C5	AG.RT.C5	0.631	0.055
20100129.PD.PI	PD.PI.C6	PD.PI.C6	0.25	0.034	20100226.AG.RT	AG.RT.C6	AG.RT.C6	0.201	0.015
20100129.PD.PI	PD.PI.C7	PD.PI.C7	0.176	0.019	20100226.AG.RT	AG.RT.C7	AG.RT.C7	0.159	0.013
20100129.PD.PI	PI.C1	0.0625	0.928	0.037	20100226.AG.RT	RT.C1	0.078125	1.033	0.136
20100129.PD.PI	PI.C2	0.125	0.753	0.045	20100226.AG.RT	RT.C2	0.15625	1.01	0.099
20100129.PD.PI	PI.C3	0.25	0.687	0.086	20100226.AG.RT	RT.C3	0.3125	0.965	0.067
20100129.PD.PI	PI.C4	0.5	0.544	0.04	20100226.AG.RT	RT.C4	0.625	0.935	0.105
20100129.PD.PI	PI.C5	1	0.391	0.045	20100226.AG.RT	RT.C5	1.25	0.621	0.064
20100129.PD.PI	PI.C6	2	0.283	0.042	20100226.AG.RT	RT.C6	2.5	0.216	0.022
20100129.PD.PI	PI.C7	4	0.207	0.009	20100226.AG.RT	RT.C7	5	0.178	0.011
20100202.AG.AK	AG.AK.C1	AG.AK.C1	0.871	0.08	20100226.PI.SL	PI.C1	0.0625	0.929	0.147
20100202.AG.AK	AG.AK.C2	AG.AK.C2	0.86	0.064	20100226.PI.SL	PI.C2	0.125	1.002	0.299
20100202.AG.AK	AG.AK.C3	AG.AK.C3	0.863	0.104	20100226.PI.SL	PI.C3	0.25	0.896	0.047
20100202.AG.AK	AG.AK.C4	AG.AK.C4	0.843	0.116	20100226.PI.SL	PI.C4	0.5	0.708	0.118
20100202.AG.AK	AG.AK.C5	AG.AK.C5	0.713	0.06	20100226.PI.SL	PI.C5	1	0.618	0.11
20100202.AG.AK	AG.AK.C6	AG.AK.C6	0.406	0.069	20100226.PI.SL	PI.C6	2	0.42	0.036
20100202.AG.AK	AG.AK.C7	AG.AK.C7	0.27	0.044	20100226.PI.SL	PI.C7	4	0.333	0.052
20100202.AG.AK	AG.C1	0.078125	1.027	0.034	20100226.PI.SL	PI.SL.C1	PI.SL.C1	0.901	0.057
20100202.AG.AK	AG.C2	0.15625	1.053	0.071	20100226.PI.SL	PI.SL.C2	PI.SL.C2	0.876	0.045
20100202.AG.AK	AG.C3	0.3125	1.052	0.059	20100226.PI.SL	PI.SL.C3	PI.SL.C3	0.812	0.105
20100202.AG.AK	AG.C4	0.625	0.967	0.03	20100226.PI.SL	PI.SL.C4	PI.SL.C4	0.626	0.04
20100202.AG.AK	AG.C5	1.25	0.972	0.046	20100226.PI.SL	PI.SL.C5	PI.SL.C5	0.447	0.02
20100202.AG.AK	AG.C6	2.5	0.955	0.082	20100226.PI.SL	PI.SL.C6	PI.SL.C6	0.285	0.022
20100202.AG.AK	AG.C7	5	0.861	0.051	20100226.PI.SL	PI.SL.C7	PI.SL.C7	0.222	0.025
20100202.AG.AK	AK.C1	0.3125	0.983	0.036	20100226.PI.SL	SL.C1	0.078125	1.082	0.018
20100202.AG.AK	AK.C2	0.625	0.895	0.056	20100226.PI.SL	SL.C2	0.15625	0.961	0.058
20100202.AG.AK	AK.C3	1.25	0.887	0.081	20100226.PI.SL	SL.C3	0.3125	0.992	0.067
20100202.AG.AK	AK.C4	2.5	0.785	0.072	20100226.PI.SL	SL.C4	0.625	1.054	0.048
20100202.AG.AK	AK.C5	5	0.587	0.034	20100226.PI.SL	SL.C5	1.25	1.038	0.092
20100202.AG.AK	AK.C6	10	0.399	0.04	20100226.PI.SL	SL.C6	2.5	1.065	0.06
20100202.AG.AK	AK.C7	20	0.277	0.034	20100226.PI.SL	SL.C7	5	1.01	0.074
20100202.AG.ER	AG.C1	0.078125	1.027	0.034	20100226.RT.SR	RT.C1	0.078125	1.033	0.136

Table S2 continued

Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD	Experiment	Condition	Drug Dose (μM)	Effect (rel. to DMSO)	STD
20100202.AG.ER	AG.C2	0.15625	1.053	0.071	20100226.RT.SR	RT.C2	0.15625	1.01	0.099
20100202.AG.ER	AG.C3	0.3125	1.052	0.059	20100226.RT.SR	RT.C3	0.3125	0.965	0.067
20100202.AG.ER	AG.C4	0.625	0.967	0.03	20100226.RT.SR	RT.C4	0.625	0.935	0.105
20100202.AG.ER	AG.C5	1.25	0.972	0.046	20100226.RT.SR	RT.C5	1.25	0.621	0.064
20100202.AG.ER	AG.C6	2.5	0.955	0.082	20100226.RT.SR	RT.C6	2.5	0.216	0.022
20100202.AG.ER	AG.C7	5	0.861	0.051	20100226.RT.SR	RT.C7	5	0.178	0.011
20100202.AG.ER	AG.ER.C1	AG.ER.C1	1.027	0.069	20100226.RT.SR	RT.SR.C1	RT.SR.C1	1.021	0.069
20100202.AG.ER	AG.ER.C2	AG.ER.C2	1.024	0.08	20100226.RT.SR	RT.SR.C2	RT.SR.C2	0.959	0.117
20100202.AG.ER	AG.ER.C3	AG.ER.C3	1.042	0.097	20100226.RT.SR	RT.SR.C3	RT.SR.C3	0.755	0.055
20100202.AG.ER	AG.ER.C4	AG.ER.C4	1.1	0.113	20100226.RT.SR	RT.SR.C4	RT.SR.C4	0.822	0.095
20100202.AG.ER	AG.ER.C5	AG.ER.C5	0.96	0.103	20100226.RT.SR	RT.SR.C5	RT.SR.C5	0.733	0.092
20100202.AG.ER	AG.ER.C6	AG.ER.C6	0.985	0.14	20100226.RT.SR	RT.SR.C6	RT.SR.C6	0.221	0.032
20100202.AG.ER	AG.ER.C7	AG.ER.C7	0.833	0.108	20100226.RT.SR	RT.SR.C7	RT.SR.C7	0.13	0.01
20100202.AG.ER	ER.C1	0.078125	1.01	0.025	20100226.RT.SR	SR.C1	0.078125	1.13	0.085
20100202.AG.ER	ER.C2	0.15625	1.053	0.037	20100226.RT.SR	SR.C2	0.15625	1.069	0.095
20100202.AG.ER	ER.C3	0.3125	1.026	0.038	20100226.RT.SR	SR.C3	0.3125	1.168	0.088
20100202.AG.ER	ER.C4	0.625	1.019	0.048	20100226.RT.SR	SR.C4	0.625	1.183	0.135
20100202.AG.ER	ER.C5	1.25	1.001	0.062	20100226.RT.SR	SR.C5	1.25	1.23	0.091
20100202.AG.ER	ER.C6	2.5	0.969	0.069	20100226.RT.SR	SR.C6	2.5	1.174	0.052
20100202.AG.ER	ER.C7	5	0.949	0.114	20100226.RT.SR	SR.C7	5	1.109	0.085
20100202.AG.GF	AG.C1	0.078125	1.027	0.034	20100226.SL.SR	SL.C1	0.078125	1.082	0.018
20100202.AG.GF	AG.C2	0.15625	1.053	0.071	20100226.SL.SR	SL.C2	0.15625	0.961	0.058
20100202.AG.GF	AG.C3	0.3125	1.052	0.059	20100226.SL.SR	SL.C3	0.3125	0.992	0.067
20100202.AG.GF	AG.C4	0.625	0.967	0.03	20100226.SL.SR	SL.C4	0.625	1.054	0.048
20100202.AG.GF	AG.C5	1.25	0.972	0.046	20100226.SL.SR	SL.C5	1.25	1.038	0.092
20100202.AG.GF	AG.C6	2.5	0.955	0.082	20100226.SL.SR	SL.C6	2.5	1.065	0.06
20100202.AG.GF	AG.C7	5	0.861	0.051	20100226.SL.SR	SL.C7	5	1.01	0.074
20100202.AG.GF	AG.GF.C1	AG.GF.C1	0.895	0.072	20100226.SL.SR	SL.SR.C1	SL.SR.C1	1.121	0.128
20100202.AG.GF	AG.GF.C2	AG.GF.C2	0.895	0.078	20100226.SL.SR	SL.SR.C2	SL.SR.C2	0.987	0.079
20100202.AG.GF	AG.GF.C3	AG.GF.C3	0.857	0.077	20100226.SL.SR	SL.SR.C3	SL.SR.C3	1.07	0.157
20100202.AG.GF	AG.GF.C4	AG.GF.C4	0.938	0.083	20100226.SL.SR	SL.SR.C4	SL.SR.C4	0.967	0.1
20100202.AG.GF	AG.GF.C5	AG.GF.C5	0.799	0.05	20100226.SL.SR	SL.SR.C5	SL.SR.C5	0.967	0.124
20100202.AG.GF	AG.GF.C6	AG.GF.C6	0.552	0.062	20100226.SL.SR	SL.SR.C6	SL.SR.C6	0.922	0.086
20100202.AG.GF	AG.GF.C7	AG.GF.C7	0.24	0.023	20100226.SL.SR	SL.SR.C7	SL.SR.C7	0.868	0.107
20100202.AG.GF	GF.C1	0.3125	1.001	0.04	20100226.SL.SR	SR.C1	0.078125	1.13	0.085
20100202.AG.GF	GF.C2	0.625	0.976	0.063	20100226.SL.SR	SR.C2	0.15625	1.069	0.095
20100202.AG.GF	GF.C3	1.25	1.042	0.113	20100226.SL.SR	SR.C3	0.3125	1.168	0.088
20100202.AG.GF	GF.C4	2.5	0.93	0.111	20100226.SL.SR	SR.C4	0.625	1.183	0.135
20100202.AG.GF	GF.C5	5	0.903	0.116	20100226.SL.SR	SR.C5	1.25	1.23	0.091
20100202.AG.GF	GF.C6	10	0.702	0.084	20100226.SL.SR	SR.C6	2.5	1.174	0.052
20100202.AG.GF	GF.C7	20	0.366	0.058	20100226.SL.SR	SR.C7	5	1.109	0.085

Table S3: **Combination index (CI) scores.** The CI scores calculated from cell viability based on cell metabolic activity measurements of pairwise drug perturbations. CI scores were determined at EC50 levels. Standard deviation (Stdev) was based on CI scores determined at EC45, EC50, and EC55. In some cases the CI scores could not be determined ('nan').

Inhibitor	Inhibitor	CI	Stdev	Category
IGF1Ri	AKTi	1.157	0.3078	Additive
IGF1Ri	ERKi	nan	nan	nan
IGF1Ri	EGFRi	0.7361	0.0043	Synergistic
IGF1Ri	HDACi	0.901	0.0003	Additive
IGF1Ri	PDGFRi	0.8427	0.0165	Additive
IGF1Ri	PKCi	0.8149	0.1963	Additive
IGF1Ri	CDK4i	0.7001	0.0081	Synergistic
IGF1Ri	MEKi	nan	nan	nan
IGF1Ri	STAT3i	0.5702	nan	Synergistic
IGF1Ri	METi	1.2795	0.152	Additive
AKTi	ERKi	1.3997	0.081	Additive
AKTi	EGFRi	0.7748	0.0135	Additive
AKTi	HDACi	1.9544	0.0254	Antagonistic
AKTi	PDGFRi	0.872	0.0636	Additive
AKTi	PI3Ki	1.1347	0.0537	Additive
AKTi	CDK4i	1.3034	0.0122	Additive
AKTi	MEKi	0.72	0.0366	Synergistic
AKTi	SRCi	1.0627	0.0093	Additive
AKTi	STAT3i	1.657	0.0935	Antagonistic
AKTi	METi	1.0496	0.0435	Additive
ERKi	EGFRi	0.8468	0.0092	Additive
ERKi	HDACi	0.7098	0.0213	Synergistic
ERKi	PDGFRi	1.5091	0.0539	Antagonistic
ERKi	PI3Ki	1.2268	0.015	Additive
ERKi	CDK4i	1.0053	0.0011	Additive
ERKi	MEKi	nan	nan	nan
ERKi	SRCi	nan	nan	nan
ERKi	STAT3i	1.5643	0.1973	Antagonistic
ERKi	METi	0.6513	0.0594	Synergistic
EGFRi	HDACi	1.5375	0.0235	Antagonistic
EGFRi	PDGFRi	0.9581	0.0506	Additive
EGFRi	PI3Ki	0.9142	0.0055	Additive
EGFRi	PKCi	1.0881	0.0245	Additive
EGFRi	CDK4i	1.1421	0.0331	Additive
EGFRi	MEKi	0.8693	0.0167	Additive
EGFRi	SRCi	0.9859	0.0438	Additive
EGFRi	STAT3i	0.964	0.0051	Additive
EGFRi	METi	0.8792	0.0103	Additive
HDACi	PDGFRi	1.0499	0.0181	Additive
HDACi	PI3Ki	2.8475	0.1523	Antagonistic
HDACi	PKCi	1.7978	0.0255	Antagonistic
HDACi	CDK4i	1.1389	0.0143	Additive
HDACi	MEKi	0.9775	0.0042	Additive
HDACi	SRCi	1.1415	0.0156	Additive
HDACi	STAT3i	1.1668	0.0095	Additive
HDACi	METi	1.1827	0.0571	Additive
PDGFRi	PI3Ki	1.2518	0.0199	Additive

Table S3 continued Inhibitor	Inhibitor	CI	Stdev	Category
PDGFRi	PKCi	1.1812	0.0199	Additive
PDGFRi	CDK4i	1.0959	0.0603	Additive
PDGFRi	MEKi	0.7468	0.0495	Synergistic
PDGFRi	SRCi	0.9484	0.007	Additive
PDGFRi	STAT3i	1.0543	0.0088	Additive
PDGFRi	METi	1.2437	0.0253	Additive
PI3Ki	PKCi	0.9728	0.0118	Additive
PI3Ki	CDK4i	0.9725	0.0124	Additive
PI3Ki	MEKi	0.6716	0.0651	Synergistic
PI3Ki	SRCi	1.1896	0.1729	Additive
PI3Ki	STAT3i	1.2176	0.067	Additive
PI3Ki	METi	1.3977	0.0073	Additive
PKCi	CDK4i	1.9796	0.0881	Antagonistic
PKCi	SRCi	1.1668	0.0086	Additive
PKCi	STAT3i	1.1716	0.0781	Additive
PKCi	METi	1.1029	0.0944	Additive
CDK4i	MEKi	1.1092	0.0121	Additive
CDK4i	SRCi	1.3244	0.064	Additive
CDK4i	STAT3i	0.873	0.008	Additive
CDK4i	METi	1.8164	0.1565	Antagonistic
MEKi	SRCi	nan	nan	nan
MEKi	STAT3i	0.9767	0.0017	Additive
MEKi	METi	0.5325	nan	Synergistic
SRCi	STAT3i	0.9545	0.0069	Additive
SRCi	METi	1.3005	0.0954	Additive
STAT3i	METi	1.3147	0.1032	Additive

Table S4: **Drugs used in follow-up experiments.** Drugs used in follow-up experiments are listed and the concentrations used for Western blotting (WB) and cell viability based on cell metabolic activity measurements are indicated. *Indicates the concentrations used in dose-response cell viability experiments with 2 fold serial dilutions unless otherwise stated.

Drug	Targets	Company	Product#	Conc (WB)	Conc* (cell viability)
AZD6244	MEK1	Selleckchem	1008		1 μM
Erlotinib	EGFR/HER1	Selleckchem	1023		25.6 — 0.4 μM
FR180204	ERK1/2	EMD Millipore	328007		2.5 μM
MK2206	AKT1/2/3	Selleckchem	1078		16 — 0.25 μM
NVP-AEW541	IGF1R	Selleckchem	1034	1 μM	1 μM
PD0332991	CDK4/6	Selleckchem	1116	1 μM	6.4 — 0.1 μM
R1507	IGF1R			10 μg/ml	16 — 0.25 μg/ml

Table S5: **Interactions in the prior knowledge network.** This table lists source and target nodes in the prior knowledge network and references to their interactions. For relationships involving the same protein (e.g., AKT — AKT-pSer^{473}), the references refers to the reported effect of the phosphorylation site on the activity of the protein.

Source	Target	Reference
4EBP1_pSer^{65}	cell_viability	(*60*)
AKT	AKT_pSer^{473}	(*61*)
AKT_pSer^{473}	4EBP1_pSer^{65}	(*62*)
AKT_pSer^{473}	GSK3a_b_pSer^{21}	(*63,64*)
AKT_pSer^{473}	STAT3_pTyr^{705}	(*65*)
AKT_pSer^{473}	p70S6K_pThr^{389}	(*66*)
CDK4	RB_pSer^{807}	(*67*)
EGFR	EGFR_pTyr^{992}	(*68*)
EGFR_pTyr^{992}	MEK1_2_pSer^{217}	(*69,70*)
ERK	ERK1_2_pThr^{202}_pTyr^{204}	(*71*)
GSK3a_b_pSer^{21}	RB_pSer^{807}	(*72*)
HDAC	RB_pSer^{807}	(*73*)
IGFR	IGFRB	(*74*)
IGFRB	AKT_pSer^{473}	(*75*)
IGFRB	MEK1_2_pSer^{217}	(*76*)
ERK1_2_pThr^{202}_pTyr^{204}	cell_viability	(*77*)
ERK1_2_pThr^{202}_pTyr^{204}	p70S6K_pThr^{389}	(*78*)
MEK	MEK1_2_pSer^{217}	(*79*)
MEK1_2_pSer^{217}	ERK1_2_pThr^{202}_pTyr^{204}	(*80*)
MET	MEK1_2_pSer^{217}	(*81*)
PDGFR	AKT_pSer^{473}	(*82*)
PI3K	AKT_pSer^{473}	(*83*)
PKC	PKCa_pSer^{657}	(*84*)
PKCa_pSer^{657}	p70S6K_pThr^{389}	(*85*)
RB_pSer^{807}	cell_viability	(*86*)
S6_pSer^{235}	cell_viability	(*87*)
SRC	SRC_pTyr^{527}	(*88*)
SRC_pTyr^{527}	AKT_pSer^{473}	(*89,90*)
SRC_pTyr^{527}	MEK1_2_pSer^{217}	(*91,92*)
STAT3	STAT3_pTyr^{705}	(*93*)
STAT3_pTyr^{705}	cell_viability	(*94*)
mTOR	4EBP1_pSer^{65}	(*60,95*)
p70S6K_pThr^{389}	S6_pSer^{235}	(*96*)

Table S6: **Bayesian-derived models have many interactions in common with BP-derived models.** Interactions derived using Bayesian modeling (*58, 59*) (BioLearn 1.0 software) with prior knowledge were compared to interactions present in the prior knowledge network (In prior) and the BP models (In BP). For simplicity, the directionality and the sign of the interaction was ignored. The confidence score represents the percentage of interactions present in 100 model topologies (see **fig. S12** for more information). Only interactions present in more than 50% of the Bayesian-derived models are listed. Of the 32 most confident BioLearn interactions 22 were in common with the BP-derived models. This is a highly significant overlap as only 4.4 ± 2 common interactions were recovered when drawing the 32 edges from random models of similar size as the average BP-derived network ($p < 0.0001$).

In prior	In BP	Interaction in Bayesian model	Confidence
Yes	Yes	ERK1_2_pThr^{202}_pTyr^{204} — p70S6K_pThr^{389}	100% (82% forward, 18% backward)
No	No	aAKT —> EGFR_pTyr^{992}	100%
No	No	aCDK4 —> PKCa_pSer^{657}	100%
Yes	Yes	aCDK4 —> RB_pSer^{807}	100%
No	Yes	aMEK —> RB_pSer^{807}	100%
No	Yes	aMET —> RB_pSer^{807}	100%
No	Yes	amTOR —> viability	100%
No	No	MEK1_2_pSer^{217} —> STAT3_pTyr^{705}	100% (94% forward, 6% backward)
No	Yes	4EBP1_pSer^{65} —> GSK3a_b_pSer^{21}	100% (92% forward, 8% backward)
No	Yes	IGFRB —> STAT3_pTyr^{705}	100% (91% forward, 9% backward)
Yes	Yes	p70S6K_pThr^{389} —> AKT_pSer^{473}	99% (95% forward, 4% backward)
No	No	4EBP1_pSer^{65} —> RB_pSer^{807}	98%
Yes	Yes	p70S6K_pThr^{389} —> S6_pSer^{235}	98% (95% forward, 3% backward)
No	Yes	aMEK —> ERK1_2_pThr^{202}_pTyr^{204}	97%
Yes	Yes	AKT_pSer^{473} —> SRC_pTyr^{527}	97% (95% forward, 2% backward)
No	Yes	SRC_pTyr^{527} — GSK3a_b_pSer^{21}	96% (71% forward, 25% backward)
Yes	Yes	aAKT —> AKT_pSer^{473}	96%
Yes	No	aIGFR —> AKT_pSer^{473}	96%
Yes	Yes	MEK1_2_pSer^{217} —> EGFR_pTyr^{992}	95% (88% forward, 7% backward)
No	No	MEK1_2_pSer^{217} —> 4EBP1_pSer^{65}	95% (86% forward, 9% backward)
No	No	aMET —> S6_pSer^{235}	94%
No	Yes	aEGFR —> IGFRB	93%
No	Yes	aIGFR —> 4EBP1_pSer^{65}	88%
Yes	Yes	IGFRB —> MEK1_2_pSer^{217}	82% (78% forward, 4% backward)
Yes	No	aIGFR —> IGFRB	80%
No	Yes	aMET —> p70S6K_pThr^{389}	80%
No	No	aSRC —> MEK1_2_pSer^{217}	80%
No	No	aMEK —> viability	76%
Yes	Yes	MEK1_2_pSer^{217} —> ERK1_2_pThr^{202}_pTyr^{204}	74% (73% forward, 1% backward)
No	Yes	IGFRB —> PKCa_pSer^{657}	71% (70% forward, 1% backward)
No	Yes	aHDAC —> PKCa_pSer^{657}	70%
Yes	Yes	MEK1_2_pSer^{217} —> SRC_pTyr^{527}	60% (58% forward, 2% backward)